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Metabolic Rewiring Of Macrophages Promotes Anti-Tumor Activity In Pancreatic
Cancer
Abstract
Macrophages abound in the tumor microenvironment of pancreatic cancer and other solid malignancies.
Although macrophages typically promote tumorigenesis, they also represent key targets for
immunotherapy approaches, which aim to: 1) deplete macrophages, 2) inhibit their activity, or 3) redirect
them toward an anti-tumor role. Redirecting macrophages is commonly described as a phenotypic shift
from M2 (anti-inflammatory) to M1 (pro-inflammatory) polarization. However, macrophage phenotypes
have grown increasingly diverse and only loosely describe functional roles. Here we examine the antitumor functions of macrophages – their ability to engulf and kill tumor cells – and the metabolic
dependencies of this process, using a syngeneic and fully immunocompetent tumor model of pancreatic
ductal adenocarcinoma (PDAC). In PDAC cells derived from KPC (KrasLSL.G12D/+; Trp53R172H/+; PdxCre) mice, the anti-phagocytic receptor CD47 was knocked out using transient CRISPR-Cas9 expression.
CD47 is overexpressed by tumor cells to suppress macrophage anti-tumor activity and escape cancer
immunosurveillance. Despite the critical role of CD47, we found that complete loss of CD47 in PDAC cells
did not induce macrophage engulfment in vitro, nor did it impact tumor growth in vivo. We hypothesized
that macrophages required an activated state, and found that ODN1826, a CpG oligonucleotide, could
stimulate macrophages to engulf tumor cells whether they expressed CD47 or not, and without inducing
classical M1 or M2 markers. Moreover, CpG treatment of tumor-bearing mice induced potent anti-tumor
responses that required macrophages, but not lymphocytes, natural killer cells, or dendritic cells. CpG
activation was found to promote oxidative respiration dependent on fatty acid oxidation, along with
rewiring of the Krebs cycle through the activity of ATP citrate lyase. Together, these changes represented
a hybrid of M1 and M2 metabolisms, and were critical for macrophage engulfment of PDAC cells and antitumor activity. Our findings indicate that immune activation of macrophages alter their metabolic state
rather than their M1/M2 phenotype to enable them to overcome inhibitory CD47 and carry out anti-tumor
activity.
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ABSTRACT
METABOLIC REWIRING OF MACROPHAGES PROMOTES ANTI-TUMOR
ACTIVITY IN PANCREATIC CANCER
Mingen Liu
Gregory L. Beatty
Macrophages abound in the tumor microenvironment of pancreatic cancer and other solid
malignancies. Although macrophages typically promote tumorigenesis, they also
represent key targets for immunotherapy approaches, which aim to: 1) deplete
macrophages, 2) inhibit their activity, or 3) redirect them toward an anti-tumor role.
Redirecting macrophages is commonly described as a phenotypic shift from M2 (antiinflammatory) to M1 (pro-inflammatory) polarization. However, macrophage phenotypes
have grown increasingly diverse and only loosely describe functional roles. Here we
examine the anti-tumor functions of macrophages – their ability to engulf and kill tumor
cells – and the metabolic dependencies of this process, using a syngeneic and fully
immunocompetent tumor model of pancreatic ductal adenocarcinoma (PDAC). In PDAC
cells derived from KPC (KrasLSL.G12D/+; Trp53R172H/+; Pdx-Cre) mice, the anti-phagocytic
receptor CD47 was knocked out using transient CRISPR-Cas9 expression. CD47 is
overexpressed by tumor cells to suppress macrophage anti-tumor activity and escape
cancer immunosurveillance. Despite the critical role of CD47, we found that complete
loss of CD47 in PDAC cells did not induce macrophage engulfment in vitro, nor did it
impact tumor growth in vivo. We hypothesized that macrophages required an activated
state, and found that ODN1826, a CpG oligonucleotide, could stimulate macrophages to
v

engulf tumor cells whether they expressed CD47 or not, and without inducing classical
M1 or M2 markers. Moreover, CpG treatment of tumor-bearing mice induced potent antitumor responses that required macrophages, but not lymphocytes, natural killer cells, or
dendritic cells. CpG activation was found to promote oxidative respiration dependent on
fatty acid oxidation, along with rewiring of the Krebs cycle through the activity of ATP
citrate lyase. Together, these changes represented a hybrid of M1 and M2 metabolisms,
and were critical for macrophage engulfment of PDAC cells and anti-tumor activity. Our
findings indicate that immune activation of macrophages alter their metabolic state rather
than their M1/M2 phenotype to enable them to overcome inhibitory CD47 and carry out
anti-tumor activity.
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Chapter 1: Introduction

Tumor inflammation has dual roles in governing tumorigenesis.
Tumors are characterized as wounds that never heal, commonly featuring immune
infiltrate that pervade the stroma of solid tumors.1 This infiltrate includes a diverse mix of
innate immune cells (e.g. macrophages, granulocytes, dendritic cells, etc) and adaptive
immune cells (cytotoxic T cells, helper T cells, regulatory T cells, etc) that facilitate
tumor-promoting inflammation.2 Tumor inflammation supports tumorigenesis by
reinforcing the hallmarks of cancer progression – including angiogenesis, metastasis, and
DNA damage – although these effects can also be attenuated and reversed by altering the
activity of immune cell populations.3
Under the right conditions, immune cell effectors are capable of targeting and
eradicating tumor cells through cancer immunosurveillance.4,5 Immune-mediated
clearance of tumor cells has been described as the ‘cancer immunity cycle’, a multistep
process involving the concerted activity of both innate and adaptive immunity.6
Therapeutic advances in cancer immunotherapy aim target discrete steps of the cancer
immunity cycle: 1) release of cancer cell antigens, 2) presentation by antigen presenting
cells (APCs), 3) priming and activation of T cells, 4) T cell trafficking to tumors, 5)
recognition and killing tumor cells. For example, clinical inhibitors of immune
checkpoints, which target PD-L1 and CTLA-4, sustain T cell cytolytic activity against
tumor cells.7,8 Other promising treatment modalities, such as cancer vaccines and
oncolytic viruses, stimulate release of immunogenic components from tumor cells.9,10
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Understanding mechanisms underpinning each of these steps will be imperative for
enacting the cancer immunity cycle.
Despite these advances, novel immunotherapies do not benefit all patients or all
cancer types. Systematic profiling of immune infiltrate in tumors indicate that the
heterogeneous responses of tumors to immunotherapy arise from tumor cell-intrinsic and
-extrinsic properties.11 Tumor cell-intrinsic properties include varying frequency of
mutations across cancers, which give rise to immunogenic epitopes that can be
recognized by T cells, or expression of immune checkpoint molecules that suppress
cancer immunosurveillance.12,13 Cancers that respond to checkpoint immunotherapies
(e.g. melanoma and non-small cell lung cancer) correspond with high mutational burden,
but cancers that respond poorly (e.g. pancreatic cancer) lack mutational epitopes for T
cells to target.14,15 Tumor cell-extrinsic properties include the suppression and exclusion
of cytotoxic T cells, as well as the presence of myeloid cells in the stroma that contribute
to an immunosuppressive milieu.16 In the tumor microenvironment, as in pancreatic
cancer for example, the desmoplastic tumor stroma precludes T cell entry and the
abundant myeloid infiltrate suppresses anti-tumor activity. These properties collectively
render tumors as ‘hot’ or ‘cold’, which describe the composition of immune infiltrate
governing therapeutic responsiveness.17,18
As a hallmark feature of inflammation, macrophages dominate the tumor
microenvironment of many cancers, such as pancreatic cancer.19 Macrophages commonly
restrain anti-tumor activity and mediate resistance to chemotherapy, radiotherapy, and
immunotherapy.20,21 Thus, depleting macrophages or shifting their properties represent
promising therapeutic approaches for mitigating treatment resistance and complementing
2

strategies that target tumor cells or other immune cells.22,23 Understanding the critical
determinants of macrophage function will be critical for achieving therapeutic effects
through macrophage-directed immunotherapy.

Harnessing tumor inflammation for therapeutic benefit in pancreatic cancer
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States.
Without appropriate screening measures for pancreatic cancer, approximately 80% of
patients have disseminated disease upon diagnosis and require systemic treatment with
chemotherapy.24 The five-year survival of pancreatic cancer patients remains dismal at
8.5%, despite recent clinical advances with the approval of new chemotherapy regimens
such as FOLFIRINOX (Folate + 5-Fluorouracil + Irinotecan + Oxaliplatin) and the
combination of nab-paclitaxel and gemcitabine.25,26 Thus, it is imperative to develop new
treatment modalities for pancreatic cancer that can enhance standard-of-care
chemotherapy.
However, immunotherapeutic agents that have demonstrated efficacy in other
solid tumors have largely failed to generate clinical responses in pancreatic cancer. These
agents include novel therapies targeting T cell checkpoints (e.g. CTLA-4 and PD-L1),
which have improved patient survival in melanoma, non-small cell lung cancer, bladder
cancer, kidney cancer, etc. Even though checkpoint inhibition has shown promise against
a subset of pancreatic tumors with defective DNA mismatch repair – which gives rise to
more immunogenic antigens T cell responses – pancreatic tumors more typically express
few neoantigens that are conducive for checkpoint inhibition or T cell directed
therapies.27–29
3

Despite the challenges encountered by T cell directed approaches in pancreatic
cancer, several immunotherapies have shown promise as single agents or in combination
with other treatments. For example, an agonistic antibody against co-stimulatory receptor
CD40

has

shown

clinical

benefit

in

phase

I/II

clinical

trials.30,31

In part, agonistic CD40 antibodies activate macrophages to drive the degradation of the
desmoplastic stroma commonly found in pancreatic tumors.31 Stromal degradation, in
turn, enhances the effectiveness of chemotherapy and facilitate T cell responses. 32–34
When combined with chemotherapy and checkpoint molecules, such as anti-CTLA4 and
anti-PD-L1 antibodies, CD40 agonists can promote antigen presentation and potentiate
durable anti-tumor responses in a murine model of pancreatic ductal adenocarcinoma
(PDAC).35 These studies demonstrate how immune agonists can drive a coordinated antitumor response by innate and adaptive immunity.

Activating tumor inflammation through PRRs (pattern recognition receptors)
The forerunner to modern immunotherapy can be traced to the development of
Coley’s toxins in the early twentieth century. Predating the advent of antibiotics, New
York-based surgeon Dr. William Coley observed that many of his patients who
developed erysipalis, skin infections caused by Staphylococcus bacteria, also experienced
spontaneous regressions of unresectable tumors. To test his hypothesis that inflammation
drove these tumor regressions, Dr. Coley purified crude bacterial extracts from skin
lesions (known colloquially as ‘Coley’s toxins’) and administered these to his cancer
patients.36 This treatment led to severe inflammatory responses in his patients and
occasional long-term tumor regressions. Without molecular techniques to study the
4

phenomenon that Dr. Coley observed, it would be nearly a full century before
immunotherapy would be considered a viable modality for cancer treatment.
The bacterial extracts that Dr. Coley isolated would have contained molecules
now known to activate pattern recognition receptors (PRRs) expressed in immune cells,
particularly antigen presenting cells (APCs).37 Recognition of pathogen-associated
molecular patterns (PAMPs), such as bacterial DNA motifs or cell wall components,
stimulates PRRs to trigger maturation of APCs and a potent immune response. One such
molecule is imiquimod, which activates TLR7 (Toll-like receptor 7) belonging to a
family of PRRs called Toll-like receptors (TLRs). Imiquimod is used as a clinicallyapproved agent for treating skin tumors (i.e. superficial basal cell carcinoma and
squamous cell carcinoma) by stimulating skin-resident APCs such as Langerhans cells to
mobilize an immune response.38,39
Multiple other activators of TLRs and PRRs have been investigated for their antitumor properties, particularly as adjuvants for cancer vaccines. These agonists include
bacterial or viral DNA motifs known as Poly I:C and unmethylated CpG, which activate
TLR3 and TLR9 respectively.40,41 Treatment using CpG has been examined in multiple
early-phase clinical trials for lung cancer, melanoma, and lymphoma.42–44 Though CpG
treatment exhibited promising anti-tumor activity shown in early phase studies, phase 2/3
clinical trials failed to demonstrate efficacy for CpG in combination with chemotherapy
for treating melanoma, and also induced immune-related adverse events that led to
discontinuation of studies.45 Despite these clinical setbacks, ongoing investigation has
indicated that the anti-tumor activity of CpG can be enhanced by addition of other
modalities in preclinical models. For example, stimulation with CpG and agonists
5

directed against immune checkpoint OX40,46 can potentiate potent responses that involve
adaptive immunity. Additionally, blockade of interleukin-10 receptor in conjunction with
CpG-treatment generated anti-tumor responses that were dependent on macrophages.47
Inhibition of interleukin-10 receptor critically suppresses the anti-inflammatory effect of
interleukin-10 generated upon immune activation. These data indicate that agents
targeting Toll-like receptors, such as CpG, remain a potential therapeutic for cancer
treatment, particularly for their ability to broadly activate macrophages and other immune
cells.

Tumor macrophages can adopt pro-or anti-tumor phenotypes
Tumor macrophages can adopt a pro- or anti-inflammatory role, which in turn,
inhibit or promote the growth of tumors. The opposing roles of macrophages are
commonly described pro-inflammatory M1 and anti-inflammatory M2 phenotypes.21 M1
macrophages are induced by interferon-γ and lipopolysaccharide, and are typified by their
ability to generate nitric oxide species through inducible nitric oxide synthase (iNOS),
and secretion of interleukin-12.48 These properties not only orchestrate a proinflammatory response, but also direct helper T cells toward Th1 response that supports
cytotoxic responses against tumor cells. In contrast, M2 macrophages are induced by
interleukin-4, and drive CD4 T cells toward a Th2 response associated with chronic
inflammation conducive to tumor growth. Additionally, M2 macrophages express
arginase-1 that catabolizes arginine to inhibit the production of nitric oxide.49
Macrophages can further exert immunosuppressive effects by generating indoleamine-
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pyrrole 2,3-dioxygenase, an enzyme that critically depletes the tumor microenvironment
of tryptophan necessary for T cell responses.50
The functional effect of macrophage polarization varies widely under different
physiologic and pathologic contexts. In normal physiological roles, macrophages in the
spleen facilitate clearance of senescent red blood cells, and osteoclasts regulate the
breakdown and homeostasis of bone. However, in atherosclerotic disease, inflammation
driven by M1 macrophages ultimately facilitate uptake of lipids by macrophages, leading
to a foam cell phenotype associated with M2 macrophages. Macrophages in tumor
microenvironments commonly adopt an M2 phenotype that not only restrain adaptive
immune responses, but also enhance tumor vascularity and metastatic spread.21,51 In
diseases such as diabetes, perturbations of nutrient availability give rise to unique states
of metabolic activation that are distinct from classical M1 and M2 phenotypes.52,53 When
using systems approaches to assess the response of human macrophages to a wide range
of inflammatory stimuli, macrophages were found to exhibit a spectrum of activation,
which were characterized by gene expression changes in core metabolic processes. These
studies support a recent paradigmatic shift away from distinct classes of macrophage
polarity, and toward an appreciation for how macrophage activation spans a spectrum of
phenotypes.
The association between macrophage polarization and function is poorly
understood. For example, M2 macrophages that are commonly associated with a protumor role surpass M1 macrophages in performing antibody-directed cellular
phagocytosis – or engulfment of tumor cells opsonized with antibodies. In macrophages
cultured from human donors, this superior phagocytic ability of M2-polarized
7

macrophages was dependent on the Fc-receptor, as genetic variants in Fc-receptors
associated with loss of augmented activity. Activation of macrophages can also
coordinately regulate effector functions, such as cytokine secretion and bacterial
clearance. Consequently, stimulation with LPS and CpG induces changes in a conserved
network of lipid regulators that are associated with altered membrane fluidity and
cytokine secretion. These data indicate that stimuli that activate phenotypic polarization
also impact macrophage function, although the mechanisms underlying this relationship
require further elucidation.
Macrophage activation through TLRs stimulates inflammatory functions beyond
cytokine secretion, but also promote macrophage functions such as phagocytosis. 54,55 For
example, TLR activation can stimulate a unique phagocytic program in macrophages and
other phagocytes known as LC3 (Light Chain 3-like protein)-associated phagocytosis
(LAP).56 Specifically, LAP is activated by TLR 1/2, 2/6, and 4 pathways, and induces the
aggregation of LC3 and other autophagy-associated machinery to phagolysosomes.57
These LC3-associated vesicles fuse with phagosomes to facilitate degradation of the
phagocytic load, and demonstrate how metabolically reprogramming regulates
macrophage function.58 This process is distinct from autophagy in that LC3-vesicles
facilitate breakdown of internalized loads during LAP, rather than degradation of
cytosolic components as observed during canonical autophagy.59 LAP operates during
macrophage engulfment of bacteria and fungi (e.g. Aspergillus fumigatus), and during
immunologically silent clearance of apoptotic cells.54,59 TLR9 stimulation has also been
shown to trigger production of type I interferons dependent on the formation of LC3associated phagosomes.59 The ability of select TLR pathways to induce unique modes of
8

phagocytosis indicates that TLR-based therapies may likewise modulate macrophage
function in the setting of cancer.

Linking macrophage phenotype with macrophage metabolism
The phenotypic shift accompanying macrophage activation also corresponds
changes to metabolic alterations. For example, M1 macrophages often adopt a glycolytic
phenotype upon stimulation to bacterial lipopolysaccharide (LPS).51 Metabolic features
of M1 macrophages include increased glycolytic flux and lactate production,
accompanied by decreased oxidative phosphorylation and oxygen consumption.60,61
Pharmacologic inhibition of these glycolytic processes also inhibited generation of
interleukin-1β, indicating an intricate link between metabolic phenotype and macrophage
function.60
In contrast, M2 macrophages are often characterized by enhanced oxidative
phosphorylation and lipogenesis, which are stored as lipid droplets.61–63 However, other
studies contend that this oxidative phenotype is dispensable for M2 polarization using
interleukin-4.64 When assessed using approaches such as gene expression and metabolite
tracing, M1 and M2 macrophages are distinct in a range of metabolic pathways. In
addition to differences in glycolysis and Krebs cycle intermediates, M1 macrophages
exhibit elevated production of itaconate, whereas M2 macrophages upregulate de novo
synthesis of nucleotides.65 Another hallmark feature of M2 activated macrophages is their
elevated usage of glutamine-derived substrates,66 in which glutaminolysis leads to
incorporation of carbons from glutamine into the Krebs cycle. Activation of this pathway
is critical for the function of M2 macrophages in clearing microbial infection in vitro and
9

in vivo. Thus, not only do classical M1 and M2 macrophage phenotypes exhibit distinct
metabolic profiles, but they also integrate multiple substrate pathways to support their
functions.
The association between macrophage phenotype and metabolism resembles the
link observed in other immune cells. T cell activation can direct phenotypic and
functional shifts that are underpinned by metabolic changes. For example, effector T cells
show an increased reliance on glycolytic metabolism,67 as opposed to memory T cells,
which exhibit a dependence on fatty acid metabolism, acetate consumption, and
autophagy.68–70 Similarly, for myeloid derived suppressor cells in cancer, fatty acid
oxidation is critical for their immunosuppressive function.71 The metabolic shift of
immune cells can also be elicited by TLR stimulation; plasmacytoid dendritic cells
treated with CpG can activate fatty acid oxidation to enhance production of type 1
interferons.72 Together, these findings underscore how metabolic changes in immune
cells can broadly regulate their phenotype and function.

Pro-and anti-phagocytic immune checkpoints govern macrophage function
Macrophage function is governed immune checkpoints. The phagocytic function
of macrophages is determined by the balance of pro- and anti-phagocytic signals.73,74 Prophagocytic cues include Fc-receptor signaling upon engagement of macrophage Fcreceptors by antibodies bound to cells targeted for phagocytosis.75,76 Another major prophagocytic signal regulating macrophage phagocytic function are oxidized phospholipids
on the cell membrane of senescent cells (e.g. red blood cells).77,78 As phospholipids
accumulate on the outer cell membrane, mediated by the activity of flippase enzymes,
10

these phospholipids are recognized by TIM4-receptors expressed by macrophages and
stimulate phagocytosis.79–81 Similarly, calreticulin is a second major pro-phagocytic
signal present on the surface of apoptotic and tumor cells, which engages lipoprotein
receptor-related protein on macrophages and promote phagocytosis.55,73 Finally, a third
pro-phagocytic signal can be induced by MerTK (Mer Tyrosine Kinase) expressed by
phagocytes, which can bind multiple ligands and promote clearance of apoptotic
cells.82,83 The mechanisms by which multiple pro-phagocytic pathways integrate in
macrophages to coordinate their activity remains unclear.
These pro-phagocytic signals are counterbalanced by negative regulators such as
CD47.84 CD47 is a ubiquitously expressed receptor on all cells, and suppresses
phagocytic activity by binding SIRPα (Signal Regulatory Protein α)-receptor found on
phagocytes. Upon binding, SIRPα triggers phosphorylation and activation SHP1
phosphatase.77 SHP-1 activation in turn suppresses the phosphorylation of myosin-IIa,
which represents a critical step required to form a phagocytic cup around cells targeted
for engulfment.85 CD47 has also been implicated in conferring protection from radiation
damage in tissues and cellular stemness as well. 86,87
The anti-phagocytic role of CD47 is coopted by multiple types of tumors as a
mechanism of immune escape. Tumor cells can evade cancer immunosurveillance by the
immune system through overexpression of CD47, which can function as a prognostic of
survival for patients with these cancers.88 In preclinical models, inhibition of CD47 and
SIRPα binding using a CD47-blocking antibody can generate potent anti-tumor responses
in xenograft human tumors implanted into NSG (NOD scid gamma) mice lacking natural
killer, B, and T cells.89 Similar agents, such as a fusion SIRPα-Fc protein containing
11

SIRPα analog fused to an Fc domain, can block CD47-SIRPα binding while
simultaneously providing a pro-phagocytic signal through the Fc-receptor.90 The efficacy
of these agents can be bolstered by concomitant treatment with tumor binding antibodies
– including clinically available antibodies (e.g. rituximab, cetuximab, etc) directed
against surface proteins found to be commonly overexpressed in tumors.91 These CD47targeting treatment combinations can eradicate cancer stem cells and significantly
enhance survival in preclinical studies.89
Administration of CD47-blocking antibody can elicit pleiotropic anti-tumor
effects. In xenograft models of glioblastoma, CD47-blockade induces macrophage antitumor activity that is characterized by polarization of tumor macrophages toward an M1
phenotype associated with anti-tumor activity.92 The pro-phagocytic role of CD47blockade can be similarly enhanced by stimulating macrophages with agonists of Tolllike receptors (TLRs).55 In particular, multiple TLR agonists, including activators of TLR
4, 7, and 9 enhanced the phagocytic capacity of macrophages in conjunction with CD47
blockade. The pro-phagocytic effect of TLR stimulation on macrophages was preserved
with genetic ablation of tumor-expressed CD47, indicating independent of the role Fcreceptor engagement. Rather, TLR-stimulation of macrophages promotes their secretion
of calreticulin that provide a pro-phagocytic signal for tumor cell engulfment. CD47blockade not only elicits phagocytosis by macrophages, but also induces antigen
presentation to T cells and a memory response against tumors. The ability of CD47blockade to stimulate antigen presentation to T cells is not limited to macrophages,
however, but can also extends to dendritic cells.93 In syngeneic murine tumor models,
administration of anti-CD47 antibody led to inhibition of immunogenic tumors mediated
12

by DC activation of T cells. These findings highlight how the broad effects of CD47blockade and how it may potentially complement immune agonists in novel therapeutic
regimens.
The therapeutic benefit of targeting macrophage checkpoints such as CD47 has
also elicited concern about the potential safety and escape mechanisms of using these
approaches in cancer. For example, CD47 is also a critical regulator of engulfment and
clearance of red blood cells by splenic macrophages; thus, systemic inhibition of CD47SIRPα may give rise to anemia from accelerated destruction of red blood cells.
Preclinical evidence suggests that anemia is transient, with red blood cell counts
rebounding and stabilizing after sustained treatment with CD47-blocking antibodies.89
Tumor cell resistance to CD47 treatment also remains a concern for translational
applications.94 Recent studies indicate that CD47-blockade is particularly effective
against subsets of lymphomas (e.g. T-cell lymphoma), but may be less effective against
other tumor types, including many solid tumors. This finding is consistent with xenograft
models of pancreatic cancer, in which CD47-blockade alone failed to stimulate antitumor responses against human tumors.95 Rather, the addition of gemcitabine and nabpaclitaxel was required to eliminate cancer stem cells in pancreatic tumors and generate
robust anti-tumor responses. Other mechanisms by which tumors escape macrophage
phagocytosis, include downregulation of MHC I on tumor cells, which can provide an
additional pro-phagocytic signal. Collectively, this evidence underscores how
macrophage anti-tumor activity is governed by multiple inputs, and that combination
approaches to elicit this activity and overcome resistance.
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Dissertation Objectives
Cancer immunotherapies have the potential to harness tumor inflammation for
therapeutic benefit. A major driver of tumor inflammation is macrophages in the tumor
microenvironment, which can be stimulated to mediate anti-tumor activity by treatment
with immune agonists (e.g. TLR agonists) or inhibitors of macrophage checkpoints (e.g.
blockade of tumor-expressed CD47). Although macrophage anti-tumor activity is
associated with polarization toward classical M1 and M2 phenotypes, it is increasingly
understood that macrophages span a spectrum of activation states with distinct metabolic
features. The goal of this thesis is to understand how metabolic changes underlying
macrophage anti-tumor function (i.e. phagocytosis) can be leveraged for enhancing
immune-based treatments for cancer through the following specific aims:
1. Understand how CpG stimulation potentiates macrophage anti-tumor activity
against pancreatic cancer cells that are resistant to CD47-inhibition
The majority of studies examining the impact of CD47-inhibition on
macrophages focus on xenograft human tumors in immunocompromised NSG mice.
Data on CD47-inhibition in immunocompetent models of cancer are lacking. Here,
we examine the role of CD47-inhibition using antibody blockade and genetic
knockout in a syngeneic model of PDAC. Surprisingly, PDAC tumor growth can
resist CD47-blockade as well as complete loss of CD47. Thus, we hypothesize that
tumor macrophages may lack an activated anti-tumor phenotype and require
additional stimuli.
Using in vitro co-culture assays, we show that macrophage activation with CpG
can promote phagocytosis of PDAC cells expressing or lacking CD47, which was
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generalizable to other cancers, including immunologically ‘hot’ and ‘cold’ tumors.
We also demonstrate that administration of CpG generates anti-tumor activity in vivo,
which was revealed to be dependent on macrophages in depletion studies. These
findings demonstrate that inducing an activated phenotype in macrophages can
overcome CD47 expressed by tumor cells as a mechanism of immune escape.
2. Determine the metabolic changes imbued by CpG that support macrophage
anti-tumor activity against PDAC cells.
Immune activation shapes the metabolism and phenotype of macrophages and
other cell types (DCs, T cells, MDSCs, etc). For example, TLR activation with CpG
rewires the metabolism of lipids in DCs and macrophages. However, the role of
cellular metabolism in regulating macrophage function in the setting of cancer
remains poorly understood. We hypothesize that stimulating an anti-tumor phenotype
in macrophages with CpG will promote metabolic changes that critically support their
phagocytic capacity.
To understand the cellular effects of CpG activation, we assess phenotypic
changes of macrophages with respect to glycolytic flux and oxidative respiration. We
further interrogate the central carbon metabolism of CpG-activated macrophages by
examining the pools of short chain CoA-labeled metabolites. From these findings we
find pleiotropic changes elicited by CpG that are essential for anti-tumor function, as
demonstrated by pharmacologic inhibition.
Together, our findings underscore how metabolic rewiring of macrophages
through CpG activation coordinates engulfment of tumor cells. This approach for
enhancing macrophage anti-tumor function represents a therapeutic strategy that
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could

complement

CD47-inhibitory

agents

or

other

immunotherapies

in

immunologically ‘hot’ and ‘cold’ tumors. Finally, the association between
macrophage metabolism and function may impact other aspects of cellular biology
(e.g. membrane biology, epigenetics, etc) that deserve to be assessed in the context of
macrophage-based immunotherapies.
Figures
Figure 1: Beyond M1 and M2, macrophage anti-tumor potential defined by
metabolic and functional features.

Figure 1: Macrophages regulate tumor growth through multiple functions (e.g.
phagocytosis of tumor cells, angiogenesis, producing anti-inflammatory cytokines, etc).
In turn, these pro- and anti-tumor roles of macrophages are modulated by metabolic cues
– including hypoxia, glucose, lactate, lipids, and amino acids present in the tumor
microenvironment.
16

17

Chapter 2: Therapeutic Strategies for Harnessing Tumor Inflammation

Abstract
Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation. The
fifth—functio laesa, or loss of function—was promulgated by Rudolf Virchow, who, in
the 19th century, also noted an intricate link between inflammation and cancer. However,
the role of cancer inflammation in driving loss of therapeutic efficacy has only recently
been fully appreciated, as a result of molecular and immunohistochemical approaches
applied in clinical medicine and the availability of novel agents for modulating
inflammation. This review focuses on clinical evidence from solid malignancies that have
shaped our view of how the immune system regulates cancer development, progression,
and response to treatment. Understanding the multifaceted relationship between
inflammation and patient outcomes has the potential to advance prognostic tools and
uncover therapeutic opportunities for improving clinical outcomes.

Introduction
Since Virchow’s early observations in the 19th century associating inflammation
with malignancy, clinical studies have identified inflammatory conditions (e.g. colitis,
gastritis, pancreatitis, hepatitis, and esophagitis) as key risk factors for the development
of cancer.96 Inflammation marked by the recruitment of leukocytes, particularly
neutrophils, macrophages, and eosinophils, is a near universal hallmark of cancer that is
directed by malignant cells which seek to establish a microenvironment that is conducive
to survival, growth, and metastasis. This inflammatory reaction can also act as a barrier to
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the efficacy of cytotoxic and immunotherapeutic interventions. As a result, increasing
attention has been placed on strategies designed to ablate or redirect tumor-infiltrating
inflammatory cells in order to improve clinical outcomes. In this review, we discuss the
clinical implications of cancer inflammation and emerging interventions that disengage
elements of therapeutic resistance imparted by inflammation in cancer.
Prognosis: Linking inflammation with oncology outcomes
Inflammation is a negative prognostic factor across multiple cancers and has been
associated with cachexia, muscle wasting, fatigue, decreased cognitive ability and a
reduced quality-of-life.97,98 Given the link between inflammation and cancer, several
large clinical studies have evaluated biomarkers of inflammation for their prognostic
value. For example, C-reactive protein (CRP) has been extensively studied as a marker
of inflammation. Similarly, albumin is an acute phase reactant which decreases in the
setting of a systemic inflammatory response. Together, elevated CRP and
hypoalbuminemia are defining measures of the modified Glasgow Prognostic Score
(mGPS) which has been validated across more than 70 studies involving over 31,000
cancer patients with a wide-range of malignancies.99 Increased CRP (>10 mg/l) and
decreased albumin levels (<35 g/l) – and consequently, a higher mGPS score – is
associated with worse overall survival in patients with inoperable non-small cell lung
cancer, independent of tumor staging and performance status. Higher mGPS scores also
correlate with poorer quality-of-life and decreased nutritional status in multiple
malignancies.99 In addition, mGPS has recently been explored for its value in predicting
therapeutic response. In patients with rectal cancer undergoing neoadjuvant
chemotherapy, mGPS was strongly associated with pathologic response to treatment.100 A
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post hoc analysis of patients with gemcitabine-resistant metastatic pancreatic cancer,
treated with capecitabine and ruxolitinib on a randomized Phase II study, also
demonstrated a positive correlation between overall survival and mGPS.101 However, a
subsequent Phase III study investigating this same treatment combination and
incorporating mGPS as an inclusion criteria was terminated early due to a lack of data
confirming a role for CRP in selecting patients most likely to respond to therapy.102 Thus,
mGPS is a strong prognostic determinant for cancer patients but its role as a predictor of
treatment response and in guiding anti-inflammatory interventions remains ill-defined.
Another measure of cancer inflammation with clinical significance is the
neutrophil-to-lymphocyte ratio (NLR).103 In patients with solid malignancies, a high NLR
correlates with a poor prognosis. The NLR has also been shown to predict outcomes in
advanced colorectal cancer patients receiving chemotherapy and has been used as a
predictor of tumor recurrence and progression.104,105 However, the prognostic potential of
the NLR may not apply to all therapeutic scenarios. For example, in an unplanned
secondary analysis of patients with muscle-invasive bladder treated on a randomized
Phase 3 study with or without neoadjuvant chemotherapy, the NLR was not found to be
prognostic of overall survival benefit from neoadjuvant chemotherapy.106 In general,
though, the NLR describes a balance between innate and adaptive immunity, wherein an
accumulation of neutrophils and/or diminution in lymphocytes portends an immune state
that is less effective in controlling tumor progression.
The quality of the immune response to cancer has also been explored as a
prognostic marker. Among the many cell types observed in tumors, high densities of
CD3+ CD8+ T cells displaying a CD45RO+ memory phenotype correlates with improved
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clinical outcomes.2,107 Taking advantage of this observation, the Immunoscore is a
prognostic factor that can be incorporated into routine testing and involves
immunohistochemical analysis to detect the density and location of CD3+ and CD8+ cells
in tumor tissue.108 An increased density of CD3+ and CD8+ cells in the core versus
invasive margin of the tumor correlates with the best prognosis. Compared to the
AJCC/UICC TNM-classification system, the Immunoscore has demonstrated improved
prognostic significance.107 In addition, it was recently found to be a better predictor of
overall survival than microsatellite instability.109 Moreover, CD3+ CD8+ T cell infiltration
in melanoma is associated with treatment response to PD1/PDL1 checkpoint
immunotherapy.110 An ongoing international effort is underway to validate the
Immunoscore metric for colorectal carcinoma.
Together, the laboratory-based metrics described above and summarized in Table
1 underscore the prognostic utility of the immune reaction to cancer, ranging from
features of systemic inflammation detected in the peripheral blood to the quality of the
cellular immune infiltrate detected in tumors. Moving forward, efforts are underway that
aim to apply molecular profiling and multiplex imaging analyses to identify unique
features of the inflammatory reaction to cancer for guiding treatment and predicting
subsequent clinical outcomes.
Inhibiting inflammation for cancer prevention and treatment
The link between inflammatory markers and treatment resistance obviates the
potential for targeting key inflammation pathways and improving patient outcomes.
Strategies to intervene on cancer inflammation may (i) deplete elements of the
inflammatory response or block its recruitment to tumors, (ii) inhibit components of the
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pro-tumorigenic and immunosuppressive phenotype of inflammation, or (iii) redirect
inflammation with properties that are tumor inhibitory, immune stimulatory, or both
(Figure 2).111
Targeting inflammation for cancer prevention. Early evidence for clinical benefit
achieved with targeting inflammation was seen in a prospective cohort study of aspirin
use among colon cancer patients, for whom low-dose aspirin use correlated with reduced
fatality.112 Aspirin irreversibly inactivates the cyclooxygenase (COX) enzyme that is
required for prostaglandin synthesis, an important mediator of inflammation. This
prophylactic effect seen with aspirin in colon cancer has been extended to randomized
controlled studies comparing aspirin versus placebo among carriers of Lynch syndrome, a
hereditary condition with high predisposition for colorectal cancer. In the randomized
CAPP2 trial, daily aspirin use for at least 2 years significantly reduced the incidence of
colorectal cancer as well as other Lynch syndrome cancers after almost 5 years of followup.113 An observational study of patients with Lynch syndrome included in the Colon
Cancer Family Registry also showed a reduced risk for colorectal cancer among patients
taking aspirin.114 The ongoing CAPP3 randomized double-blinded trial is currently
evaluating the dose of aspirin needed for chemoprevention in Lynch syndrome
(NCT02497820).
The prophylactic effect of suppressing inflammation may extend beyond colon
cancer to other malignancies such as breast, prostate, and lung cancers.115 In a
population-based case-control study, the frequency and duration of using non-steroidal
anti-inflammatory agents (i.e. aspirin and ibuprofen) was associated with reduced risk for
hormone-receptor positive breast cancer.116 However, the most pronounced beneficial
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effect of aspirin has been observed in gastrointestinal malignancies, including
esophageal, stomach and colon cancer.115 For colon cancer, NCCN guidelines suggest
considering low-dose aspirin for secondary chemoprevention based on the strong data
indicating that this therapy decreases risk of recurrence and death.117
Selective COX-inhibitors may exhibit similar benefits as aspirin. For example,
COX-2 is overexpressed in many cancers including colorectal adenomatous polyps,
precursors to the development of colorectal cancer. An inhibitor against COX-2,
celecoxib, was shown to decrease the incidence of precancerous colorectal adenomas in
phase III clinical trials.118,119 Celecoxib has also been shown to reduce the risk of colon
adenocarcinoma in patients with familial adenomatous polyposis.120 However, COX-2
inhibitors are not recommended routinely at this time for sporadic or familial
adenomatous polyp prevention due to their increased risk of cardiovascular events and
current lack of phase IV data.121
Targeting inflammation for improving cytotoxic therapy. Multiple cues present
within the tumor microenvironment, including hypoxia, extracellular matrix components,
and soluble factors, can shape cancer cell biology and in turn, ignite an inflammatory
response that promotes chemoresistance. For example, the stiffness of the extracellular
matrix surrounding malignant cells can stimulate focal adhesion kinase (FAK) activity
which drives cancer cell release of chemoattractants that are important for the recruitment
of myeloid cells.122 Inhibition of FAK signaling can decrease myeloid cell infiltration
into tumors, delay tumor progression, and sensitize tumors to chemotherapy. Thus, crosstalk between malignant cells and their surrounding microenvironment is critical to
defining therapeutic resistance.
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Malignant cells respond to cytotoxic stress by releasing chemoattractants (e.g.
CCL2) and damage-associated molecular patterns, or danger signals, that attract myeloid
cells to the tumor microenvironment where they support malignant cell survival, suppress
immunosurveillance, and promote subsequent tumor outgrowth. Tumor-infiltrating
myeloid cells can mediate resistance to cytotoxic therapies including chemotherapy and
radiation.123,124 Disrupting myeloid cell recruitment by blocking chemokine/chemokine
receptor interactions (e.g. CCL2/CCR2) or myeloid growth factors (e.g. CSF-1/CSF-1R)
improves the efficacy of cytotoxic therapies in mouse models of cancer. Early promising
results also support the merit of inhibiting myeloid cell recruitment for enhancing
therapeutic efficacy in patients. In a Phase I study of patients with borderline resectable
or locally advanced pancreatic adenocarcinoma, treatment with chemotherapy in
combination with a CCR2 antagonist produced encouraging objective responses in 16
(49%) of 33 evaluable patients with local tumor control seen in 32 (97%) patients.125
Inflammatory cells may mediate chemoresistance through multiple pathways. By
releasing soluble factors (e.g. IL-6 and soluble IL-6 receptor), inflammatory cells activate
signal transducer and activator of transcription (STAT) signaling in malignant cells.126 In
models of spontaneously arising pancreatic ductal adenocarcinoma, inflammationdirected STAT signaling in cancer cells is critical for tumor development.126 Moreover,
pharmacologic inhibition of STAT signaling sensitizes tumors to chemotherapy.127
Tumor-associated macrophages can also release insulin-like growth factors that activate
IGF signaling in malignant cells and in doing so, reduce the sensitivity of cancer cells to
chemotherapy.128 Moreover, macrophages can be key orchestrators of revascularization
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after cytotoxic therapy, which promotes tumor regrowth.129 Thus, myeloid cells recruited
to the tumor microenvironment can regulate cancer cell sensitivity to cytotoxic therapies.
Based on strong preclinical data supporting a role for inflammation in therapeutic
resistance, multiple early phase clinical trials are underway investigating strategies
designed to manipulate inflammation with the intent of conditioning tumors for enhanced
responsiveness to cytotoxic therapies. Targets being explored to disrupt inflammation
include chemokine receptors (e.g. CCR2, CXCR1/CXCR2), cytokines (e.g. IL-6, IL-6R,
TNF-α, IL-1), and cellular signaling pathways (e.g. FAK, JAK1/2, CSF1R).
Targeting inflammation to restore T cell immunosurveillance in cancer. Although
chronic inflammation predisposes to cancer and can promote tumor growth and
therapeutic resistance, the immune system is inherently pliable, such that under the
appropriate conditions, it can also mediate strong anti-tumor activity. In recent years,
strategies designed to harness the therapeutic potential of the immune system have
emerged as new treatment options for some patients across a wide range of malignancies.
The robustness and durability of treatment responses produced with immune-directed
interventions has incited a revolution in cancer therapy. However, not all patients respond
to immunotherapy and in some cases, treatment responses can be transient due to
mechanisms of adaptive immune resistance, a process in which cancer cells adapt to
immune pressure.129
Anti-tumor immunity induced with immunotherapy is dependent on the existence
of tumor-specific T cells capable of infiltrating tumors and then recognizing and
eliminating malignant cells.6 This highly regulated process relies on productive and
coordinated interactions between innate and adaptive immunity. Specifically, innate
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immune cells (e.g. dendritic cells) must capture and present tumor-associated antigens in
order to prime antigen-specific T cells and stimulate their entry into tumor tissue and
subsequent effector activity. However, chronic inflammation can impair both the priming
of T cells and their subsequent effector activity by limiting effective antigen presentation
and suppressing T cell activation in tumor tissues, respectively.
Chronic inflammation can suppress the development and productivity of T cell
dependent immunosurveillance in cancer through multiple mechanisms including the
release of immunosuppressive molecules (e.g. TGF-β, IL-10, and nitric oxide),
expression of immune checkpoint molecules (e.g. PD-L1), and metabolism of amino
acids (e.g. arginine and tryptophan) that are important for T cell phenotype and
survival.130–132 Inflammatory cells can also regulate T cell entry into tumors by
establishing a physical barrier and upregulating immune checkpoint molecules including
indoleamine 2,3 dioxygenase (IDO) and PD-L1, as has been seen in colorectal cancers
with microsatellite instability.133 The co-expression of T cell immune checkpoint
molecules in tumor tissues at the interface between innate and adaptive immunity has
suggested redundancy in mechanisms of peripheral tolerance established within the tumor
microenvironment and represents the impetus for ongoing studies combining multiple
immune checkpoint inhibitors (e.g. IDO inhibition plus PD-1/PD-L1 blockade and
CTLA-4 plus PD-1/PD-L1 blockade).
In preclinical mouse models of cancer, releasing immune suppression imposed by
chronic inflammation can enhance the efficacy of T cell directed immunotherapies
including adoptive T cell therapy, immune checkpoint inhibitors, and vaccines.134–137
These findings form the basis for early phase clinical trials evaluating immune
26

checkpoint inhibitors in combination with strategies designed to inhibit the recruitment of
myeloid cells (e.g. inhibitors of FAK, CCR2, and CXCR2) or deplete myeloid cells (e.g.
CSF1R antagonists) (Table 2). Combining multiple immune modulatory agents, though,
poses challenges in determining the contribution of each therapeutic intervention to
observed clinical responses. Determining the benefit of combination therapy over
monotherapy is particularly critical in early therapeutic development and relies on
effective biomarkers, identification of patients unlikely to respond to monotherapy, or
both. However, biomarker development for immunotherapy has been particularly
challenging in contrast to targeted therapies which rely on the presence or absence of
activating mutations in driver oncogenes. For example, immunological biomarkers can
vary with time of assessment, anatomical site and even within a single lesion due to
heterogeneity of the immune reaction. Overall, the dynamic nature of the immune
reaction to cancer has made immunological biomarkers a “moving target” which is
exemplified by the difficulties encountered with standardizing assays for PD-1/PD-L1
checkpoint therapy.138 Potential biomarkers for monitoring therapies targeting cancer
inflammation include immunohistochemical and flow cytoemtry analyses that quantify:
(i) the presence and activation status of inflammatory cell subsets in tumor tissue and the
peripheral blood, (ii) the presence or absence of effector T cells in tumors, (iii) activation
of oncogenes (e.g. KRAS139) and loss of tumor suppressor genes (e.g. PTEN140) associated
with increased inflammation, (iv) signaling pathway activation in malignant and stromal
cells (e.g. phosphorylation of STAT3141 and FAK molecules122), and (v) quantification of
the matrix including vascularity and fibrosis.32 In general, biomarker development for
therapies targeting cancer inflammation will need to be informed by mechanisms of
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action of the pathways, molecules, or cell types targeted. However, benefit achieved with
inflammation-directed therapies will ultimately rely on demonstrating improvement in
standard clinical measures of response including response rates, progression free survival,
and overall survival. Nonetheless, efficiently maximizing information acquired from
tissues, peripheral blood and clinical observations during early phase studies will be
important to the development of therapies targeting inflammation, especially given the
unlikeliness that single agents targeting cancer inflammation will produce significant
clinical benefit in the advanced disease setting.
Redirecting cancer inflammation for clinical benefit
Although inflammation is most commonly considered an obstacle in cancer
therapy, the ability of innate immune cells to also acquire anti-tumor properties has
propelled the possibility that cancer inflammation may be an opportunity that can be
harnessed and redirected for therapeutic benefit. Indeed, while T cells are touted as potent
“killers” capable of seeking out malignant cells with exquisite efficiency and specificity,
actual tumor shrinkage requires removal of dead cells and matrix remodeling which is a
hallmark of innate immunity and in particular, macrophages. Macrophages demonstrate
remarkable plasticity with their biology defined by signals received from their
surrounding microenvironment.132 To this end, while macrophages can inhibit T cell
immunosurveillance in cancer, preclinical models have also demonstrated their
importance for mediating anti-tumor activity directed by tumor-infiltrating effector T
cells.142
Macrophages can be important effectors of cancer therapy through release of
cytotoxins (e.g. reactive oxygen species) and via engulfment of malignant cells.
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These mechanisms are tightly regulated by a balance of stimulatory and inhibitory
signals. Similar to immune checkpoint molecules (e.g. PD-L1) that are upregulated on
malignant cells to evade T cell immunosurveillance, macrophage-inhibitory molecules
(e.g. CD47) can also be upregulated on malignant cells and thwart the potential of innate
immunosurveillance in cancer.132,143 Multiple clinical grade antagonists have been
developed to disrupt one of these negative regulatory signals that involves CD47
interaction with SIRPα on macrophages.144 SIRPα signaling inhibits macrophage
engulfment of antibody-opsonized malignant cells and in preclinical models, disrupting
CD47-SIRPα interactions enhances the therapeutic benefit of antibody based therapies,
such as anti-CD20 antibodies (i.e. rituximab) used in the treatment of B cell
lymphomas.90
Macrophages can also be activated with anti-tumor activity using Toll-like
receptor agonists and in response to systemic activation of the CD40 pathway.31
However, in general, strategies that merely redirect cancer inflammation have
demonstrated minimal clinical benefit when translated from the laboratory to the clinic,
perhaps due to a lack of immunological memory associated with innate immunity. This
does not preclude, though, the potential of these approaches which may be particularly
relevant for tumor debulking and stabilizing disease activity. For example, redirecting
myeloid cells in cancer has recently been demonstrated to “condition” tumors for
enhanced sensitivity to chemotherapy. This finding was dependent on cytokines and
chemokines (i.e. IFN-γ and CCL2) released in response to treatment with a CD40 agonist
that subsequently stimulated a subset of peripheral blood monocytes to rapidly infiltrate
tumors and facilitate the degradation of the collagen-based extracellular matrix that
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surrounds malignant cells and can impede the efficacy of chemotherapy. 32 Redirecting
myeloid cell biology in cancer has also been found to enhance the efficacy of PD-1/PDL1 blocking antibodies, illustrating the potential of redirecting myeloid cells for
enhancing T cell dependent anti-tumor immunity.145 Thus, redirecting cancer
inflammation holds promise as an approach for remodeling tumors with enhanced
sensitivity to chemotherapy and stimulating productive T cell dependent anti-tumor
immunity.

Conclusion
From Virchow’s observations to studies connecting inflammation with cancer,
clinical evidence supports both permissive and inhibitory roles for the immune system in
regulating

cancer

development,

progression,

and

therapeutic

resistance.

The

inflammatory reaction to cancer, characterized using routine laboratory-based protocols,
has demonstrated prognostic utility. Moreover, clinical studies investigating daily aspirin
use for cancer prevention have provided a strong rationale for therapeutic strategies that
intervene on cancer inflammation. To this end, preclinical models of cancer have
highlighted the inherent plasticity of the immune system and identified novel targets for
depleting, inhibiting, and redirecting cancer inflammation. These therapeutic maneuvers
have the potential to enhance the efficacy of cytotoxic therapies and to restore an
effective communication between innate and adaptive immunity that is necessary for
productive cancer immunosurveillance. The clinical translation of agents directed at
manipulating cancer inflammation will be benefited by biomarkers based on mechanisms
of action for the signaling pathways and cellular subsets targeted. However, as cancer
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inflammation is only one element of a complex network of signals that can regulate
tumor biology, combination studies will be paramount for effectively leveraging the
potential of inflammation to serve as a therapeutic target in cancer.
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Figures
Figure 2: Strategies to target inflammation for cancer therapy.

Figure 2: Inflammatory cells (e.g. monocytes) can be targeted in cancer using
therapeutics that (1) block their recruitment to tumors (e.g. CCR2 inhibitors), (2) deplete
inflammatory cell subsets (e.g. trabectedin and CSF1R antibodies), (3) inhibit protumorigenic signaling pathways (e.g. inhibitors of BTK, CSF1R, FAK, HIF-2, IDO,
JAK, PI3K, TGF-), and (4) redirect tumor-infiltrating inflammatory cells with antitumor properties (e.g. CD40 agonists, CD47 antagonists, dectin-1 agonists, and TLR
agonists).
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Tables
Table 1: Inflammation-based prognostic scoring systems.
Scoring system
Modified Glasgow
Prognostic Score 99

Neutrophil-to-lymphocyte
ratio 103

Immunoscore 108

Approach
0 – Albumin > 3.5 g/dL and CRP < 10 mg/l
1 – Albumin < 3.5 g/dL or CRP > 10 mg/l
2 – Albumin < 3.5 g/dL and CRP > 10 mg/l
mGPS > 0 predicts decreased survival
Based on investigator-defined cut-off (e.g. NLR = 4).
NLR > cutoff predicts decreased survival.
Scale ranging from 0 to 4 describing low to high
densities of CD3+ and CD8+ cells in the center of the
tumor and invasive margin. 0, low densities in both
regions; 4, high densities in both regions.
Immunoscore = 0 displays worst overall survival
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Table 2: Active clinical studies§ combining FDA-approved immune checkpoint
inhibitors and inflammation-directed therapies.
Immune Checkpoint Target

PD-L1

Inflammation
Target
CSF1R

Active Clinical
Trials
NCT02323191

CD40

c-kit

NCT02304393
NCT02298153,
NCT02471846
NCT01738139

IDO

NCT02073123

TLR9

NCT02668770

TLR9

NCT02644967

BTK

NCT02362035

CD40

NCT02706353
NCT02526017,
NCT02452424,
NCT02713529,
NCT02880371

IDO

CTLA-4
CTLA-4 + PD-1

CSF1R

CXCR4

PD-1

NCT02923531,
NCT02907099,
NCT02826486,
NCT02823405

Dectin-1

NCT02981303

FAK

NCT02758587

HIF-2α

NCT02293980

IDO

NCT02073123,
NCT02327078,
NCT02862457,
NCT02752074,
NCT02178722

IL-10

NCT02553499

JAK1

NCT02646748

PI3Kδ

NCT02862457

TGFβR1 kinase

NCT02423343
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§

TLR3

NCT02834052

TLR9

NCT02680184,
NCT02521870

Active studies were identified on clinicaltrials.gov as of December 8, 2016

by searching for open studies including FDA-approved immune checkpoint
inhibitors in combination with an inflammation-directed therapy.
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Chapter 3: Metabolic rewiring of macrophages by CpG potentiates clearance of
cancer cells and overcomes tumor-expressed CD47

Abstract
Macrophages enforce anti-tumor immunity by engulfing and killing tumor cells.
Although these functions are determined by a balance of stimulatory (e.g. Toll-like
receptor agonists) and inhibitory signals (e.g. CD47), the role of macrophage metabolism
in defining the anti-tumor potential of macrophages is unknown. Here, we study the
capacity of macrophages to circumvent inhibitory activity mediated by CD47 expressed
on malignant cells.

We show that stimulation with CpG oligonucleotides, a TLR9

agonist, evokes changes in the central carbon metabolism of macrophages that enable
their anti-tumor activity, including engulfment of cancer cells that express elevated levels
of CD47. These changes occur without requirement for a phenotypic shift toward
classical M1 or M2 states of macrophage polarization. Rather, activation by CpG
engenders a hybrid of M1 and M2 metabolisms, featuring a dependence on elevated fatty
acid oxidation (FAO) and shunting of tricarboxylic acid (TCA) cycle intermediates for de
novo biosynthesis of lipids. This integration of multiple metabolic inputs is underpinned
by the activity of carnitine palmitoyltransferase 1A (CPT1A) and ATP citrate lyase
(ACLY), which together, impart macrophages with anti-tumor potential that can
overcome inhibitory activity from CD47 expressed on tumor cells. Our findings reveal
central carbon metabolism to be a novel determinant and potential therapeutic target for
harnessing the anti-tumor functions of macrophages.
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Introduction
Macrophages govern the immune landscape of many cancers and are key
proponents of tumor growth.21 However, macrophages can also enact anti-tumor
functions. These opposing roles are explained by the phenotypic polarity of macrophages,
which are often classified as either pro-inflammatory M1 macrophages that enforce antitumor immunity or immunosuppressive M2 macrophages that promote tumor
progression.62 While macrophages most commonly adopt a phenotype that is supportive
of tumor growth,146 their biology is pliable. As a result, under the appropriate conditions,
macrophages can be redirected with anti-tumor activity.32,147,148 The mechanisms that
determine pro- versus anti-tumor functions of macrophages, though, are still being
elucidated.
One mechanism governing pro- and anti-tumor roles of macrophages is the
balance of stimulatory and inhibitory signals. For example, a key negative regulator of
macrophage activity is CD47, a membrane-bound protein overexpressed by many
cancers.88,90 CD47 is a “don’t eat me” signal that suppresses the phagocytic activity of
macrophages upon binding SIRPα (signal regulatory protein α)-receptor present on
phagocytes.149 Blocking CD47-SIRPα binding promotes macrophage engulfment of
tumor cells and induces anti-tumor responses in multiple xenograft models.89,91 However,
in models of pancreatic ductal adenocarcinoma (PDAC), CD47-blockade as a
monotherapy has shown modest anti-tumor efficacy,95 which may be explained by the
limited pro-phagocytic effect of CD47-blockade seen in non-hematopoietic tumor
models.150 These findings suggest that additional stimuli are required to potentiate antitumor activity by macrophages.
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Macrophage stimulation is directed by cytokines and agonists of pathogen
recognition receptors, such as Toll-like receptors (TLRs), which together determine
macrophage phenotype.52 Unique combinations of stimuli have been used in vitro to
define classical phenotypic states of macrophages, such as M1 and M2. However, in
pathological settings, such as cancer, macrophages more commonly acquire phenotypes
that span a spectrum of differentiation states.53,151
When examined using systems-based approaches, macrophage phenotypes can be
distinguished by their core metabolic processes.65,151 For example, M1 macrophages rely
on glycolytic metabolism and reduced oxidative phosphorylation, whereas M2
macrophages perform de novo lipogenesis and glutaminolysis to support fatty acid
oxidation (FAO).63,152,153 Additional studies support an association between M2macrophage polarity and FAO, but indicate that these can also occur independently.64 In
particular, FAO and lipid metabolism underpin the anti-tumor functions of multiple
myeloid subsets (e.g. dendritic cells and myeloid-derived suppressor cells).71,154,155
Similarly, lipid availability can modulate macrophage engulfment of red blood cells and
macromolecules.156,157 Together, these findings underscore the potential role of
metabolism in defining myeloid cell biology, and suggest that lipid metabolism may
likewise coordinate macrophage function.
To understand the metabolic determinants that govern macrophage anti-tumor
function, we utilized metabolomic approaches and a syngeneic model of PDAC to study
macrophage engulfment of PDAC cells upon TLR stimulation. Further, we leveraged
targeted knockout of CD47 in PDAC cells to understand how macrophage activation acts
in concert with inhibition of anti-phagocytic signals present in cancer. Our studies reveal
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a novel role for metabolic pathways in regulating macrophage anti-tumor functions, and
underscore the potential of targeting macrophage metabolism for overriding inhibitory
signals used by cancer cells to evade elimination by innate immunity.

Results
Macrophage activation, but not loss of inhibitory CD47, is sufficient for anti-tumor
activity in PDAC
Macrophages can be induced with therapeutic and anti-tumor functions by
activating pro-inflammatory signaling pathways such as CD40 and TLRs.31 However,
macrophage biology is ultimately determined by a balance of stimulatory and inhibitory
signals that are sensed within the tumor microenvironment (Fig 3a). One major inhibitory
signal that is involved in suppressing macrophage anti-tumor activity is CD47, which is
overexpressed on cancer cells across a wide range of solid malignancies.89 Elevated
levels of CD47 can be detected in both mouse (Fig 4a-b) and human PDAC.95 Therefore,
we initially studied the role of CD47 as a macrophage-inhibitory signal in a murine
model of PDAC. To do this, we administered a CD47-blocking antibody via intratumoral
delivery to mice implanted with KrasG12D/+ Trp53R172H/+ mutant PDAC tumors.158 In this
fully syngeneic and immunocompetent model, antibody blockade of CD47 did not alter
tumor growth (Fig 3b). To address possible limitations in bioavailability or insufficient
blockade, expression of CD47 was ablated in PDAC cells using transient expression of
CRISPR/Cas9 (Fig 4c-d). Surprisingly, unlike models of leukemia where CD47
overexpression is a key determinant of immune escape,88 deletion of CD47 in PDAC
cells did not impact tumor engraftment or growth (Fig 3c). This observation suggested
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that mechanisms other than CD47 can regulate macrophage-dependent anti-tumor
responses in PDAC, consistent with xenograft models of this disease and other nonhematopoietic malignacies.95,150 In support of this finding, we also found that antibody
blockade of CD47 on PDAC cells did not enhance in vitro phagocytosis by murine bonemarrow derived macrophages (BMDMs) (Fig 3d).
We next hypothesized that PDAC cells may not provide sufficient activating
signals to stimulate macrophages with anti-tumor functions, and that delivery of discrete
stimuli may be necessary to induce macrophages with anti-tumor activity. We tested a
panel of Toll-like receptor (TLR) pathway agonists for their capacity to stimulate
macrophages with anti-tumor functions, such as phagocytosis. In the absence of TLR
stimulation, mock-treated BMDMs lacked the capacity to phagocytose tumor cells upon
co-culture with PDAC cells (Fig. 3e). Further, the phagocytic capacity of BMDMs
increased only modestly with 24-hour pretreatment with Pam3CSK4, Poly(I:C),
lipopolysaccharide (LPS), flagellin, and imiquimod – which stimulate TLR1 & TLR2,
TLR3, TLR4, TLR5, and TLR7, respectively (Fig 3e). In contrast, ODN1826, a Class B
CpG oligonucleotide that preferentially stimulates TLR9 expressed by macrophages and
B-cells, was found to be a potent activator of macrophage phagocytosis of PDAC cells
(Fig 3e-f). Upon increasing the duration of CpG pretreatment, CpG-activated
macrophages (CpG-BMDM) exhibited enhanced phagocytic capacity relative to mockstimulated macrophages (mock-BMDM) (Fig 3g). To ascertain the potential of CpGactivation to produce anti-tumor activity, we also performed an extended co-culture of
pretreated macrophages with PDAC cells for 48 hours. We found that CpG-activation
rendered macrophages with potent anti-tumor activity leading to a decrease in tumor cell
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survival in comparison to co-culture with mock-BMDMs (Fig 3h). Together, these data
show loss of inhibitory CD47 alone to be insufficient for unleashing anti-tumor activity
by macrophages in PDAC, and that an activated phenotype is also necessary for
macrophages to engage in anti-tumor functions.

Tumor-associated macrophages are essential for CpG-activated anti-tumor
responses
We next evaluated the in vivo anti-tumor activity of CpG on established murine
PDAC tumor growth. Treatment was initiated with intraperitoneal injection of vehicle
(PBS) or CpG on day 10 with repeated administration every other day for a total of five
doses (Fig 5a). CpG treatment potently suppressed tumor growth in two independent
PDAC tumor models (Fig. 5b), without inducing gross toxicity or lethality. This effect
was also independent of any direct cytotoxic activity of CpG on tumor cells, as treatment
of PDAC cells in vitro with supratherapeutic concentrations of CpG did not affect tumor
cell survival (Fig 6).
Repeated dosing of CpG to non-tumor bearing mice has been found to stimulate a
macrophage activation syndrome.159 Therefore, we examined the impact of treatment on
the systemic release of inflammatory cytokines. We found that in vivo delivery of CpG to
tumor-bearing mice increased pro-inflammatory cytokines in the serum, including TNFα, IFN-γ, and CCL2 (Fig 7). Consistent with this increase in inflammatory and
chemotactic factors, we observed an increase in tumor-associated macrophages following
CpG treatment (Fig 5d-e). In addition, we detected an increase in F4/80+ macrophage
phagocytosis of tumor cells in CpG-treated tumors (Fig 8). To ascertain the role of
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tumor-associated macrophages in the response to CpG treatment, we depleted distinct
macrophage populations using GW2580, an inhibitor of colony stimulating factor 1receptor (CSF1Ri), and clodronate encapsulated liposomes (CEL), which target
phagocytes residing outside of the tumor microenvironment.160 Depletion with either
CEL or CSF1Ri alone did not affect tumor outgrowth in the vehicle-treated groups (Fig
5f). In contrast, CSF1Ri abrogated the anti-tumor effect of CpG, whereas CEL did not
(Fig 5f). Similarly, we found that administration of an anti-CSF1R antibody attenuated
the CpG-induced anti-tumor response (Fig 9). These findings implicated a CSF1R+
population of macrophages, which are not targeted by liposomes, in mediating the antitumor response by CpG. Consistent with this observation, we found that CEL did not
alter macrophage presence within tumors, whereas both CSF1Ri (Fig 5d-e, Fig 9) and
anti-CSF1R antibody (Fig 8) treatment decreased the abundance of tumor-associated
macrophages.
To ascertain the possible contribution of other immune effectors, we considered a
role for lymphocytes in CpG-induced anti-tumor activity. We found that CpG did not
significantly alter the infiltration of T cell subsets (CD8+, CD4+, and CD4+ Foxp3+) into
tumors (Fig 11a-b). In addition, we detected no significant change in the expression of
activation markers, including PD-1 and Tim3, by T cells after CpG treatment (Fig 11c).
CpG-induced anti-tumor activity was also preserved in Rag2-deficient mice bearing
PDAC.1 tumors, thereby excluding a role for lymphocytes (Fig 12a). Anti-tumor activity
induced with CpG was also preserved in mice depleted of natural killer (NK) cells using
the anti-NK1.1 antibody (Fig 12c-d).161 In addition, we found that depletion of dendritic
cells (DC) using the CD11c-DTR/eGFP mouse model did not alter the anti-tumor
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response stimulated by CpG (Fig 13).162 Collectively, these data indicate that T and B
lymphocytes as well as DC and NK cells are not required for the anti-tumor response
induced by CpG.
We have previously shown a role for peripheral blood myeloid cells in mediating
anti-tumor activity against PDAC4. Thus, we investigated the expression of CSF1R on
myeloid cell populations in the peripheral blood. We found that CSF1R was expressed by
a subset of CD11b+ F4/80+ myeloid cells bearing high levels of the monocyte marker
Ly6C (Fig 14), which marks a population of myeloid cells that have been previously
shown to be recruited to PDAC tumors.32,163 Further, administration of an anti-CSF1R
antibody significantly reduced the Ly6Chi myeloid population in the peripheral blood
(Fig 14). We also found, similar to CSF1Ri and anti-CSF1R treatment, that anti-Ly6C
antibodies, which deplete the Ly6Chi monocyte population in vivo,32 blocked both the
accumulation of F4/80+ macrophages in tumors and the CpG-induced anti-tumor
response (Fig 14). Together, these data implicate myeloid cells marked by expression of
Ly6C and CSF1R in the anti-tumor activity induced by CpG.164

CpG activation of macrophages bypasses inhibitory CD47 on PDAC cells
We next sought to understand the mechanism by which CpG stimulates
macrophages with enhanced phagocytic and anti-tumor activity. We hypothesized that
CpG may alter the capacity of macrophages to respond to CD47 as a negative regulatory
signal. To test this, we assessed the impact of CpG on SIRPα expression. However, we
observed no changes in SIRPα levels with increasing duration of CpG-activation (Fig
15). We also examined the effect of CpG-activation on macrophage-inhibitory signals
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present in vitro. We found that CpG-BMDMs phagocytosed PDAC cells that either
expressed or lacked CD47, indicating that CpG stimulates macrophages with anti-tumor
activity that is independent, at least in part, of CD47 as a macrophage-inhibitory signal
(Fig 15). This finding was generalizable as CpG-activation enabled macrophage
engulfment of CD47-expressing syngeneic tumor cells derived from breast cancer,
melanoma, colorectal cancer, glioblastoma, lung cancer and lymphoma (Fig 16).
Interestingly, CD47-blockade alone also showed limited capacity to enhance macrophage
phagocytosis in these tumors, except for EL4 lymphoma cells. However, despite limited
activity by itself, we found that genetic ablation of CD47 in tumor cells (Fig 15b) as well
as CD47 blockade (Fig 16) significantly enhanced the capacity of CpG-stimulated
macrophages to phagocytose tumor cells in vitro, implying that appropriate macrophageactivation signals are critical for overcoming CD47 in non-hematopoietic tumors.
Prior studies have suggested that TLR agonists may promote phagocytic and antitumor activity by stimulating macrophages to produce calreticulin.55 To test this
possibility, we quantified calreticulin expression – including both membrane-bound and
intracellular levels – but detected no differences between mock-BMDMs and CpGBMDMs (Fig 17). Further, upon extended co-culture, CpG-BMDMs effectively
eliminated PDAC cells, with loss of CD47 expression in tumor cells providing an
additive benefit in anti-tumor activity (Fig 15c). However, the ability of CpG to promote
anti-tumor activity by macrophages despite CD47 expression on tumor cells is in contrast
with other TLR agonists, for which blockade of CD47 is critical for macrophage
activity.55
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We then asked whether disruption of CD47 may enhance the in vivo anti-tumor
activity of macrophages. Delivery of CpG to mice bearing control or CD47 knockout
(CD47 KO) tumors produced similar increases in the relative abundance of tumorassociated macrophages (Fig 15d-e). The impact of CpG on tumor growth was also
similar in tumors that expressed or lacked CD47 (Fig 3f). These findings underscore the
dominant response elicited by CpG activation of macrophages in vivo that can overcome
CD47 expressed by PDAC cells.

CpG induces a shift in macrophage metabolism
Pro-inflammatory cues can induce distinct phenotypes in macrophages. For
example, the combination of lipopolysaccharide (LPS) and interferon-γ (IFN-γ) promote
an M1 phenotype in macrophages, which is associated with pro-inflammatory and antitumor activity in cancer.51,62 In contrast, the combination of interleukin-4 (IL-4) and
interleukin-13 (IL-13) endows macrophages with M2-polarity, which suppresses
inflammation and promotes tumor growth. To study the direct effect of CpG on
macrophage polarity, we evaluated CpG-BMDMs for expression of MHC-II and CD206,
markers of M1 and M2 polarity, respectively. Surprisingly, we found that CpG did not
induce a clear shift toward either M1 or M2 phenotypes, despite the pro-phagocytic and
anti-tumor effects seen with CpG in vitro and in vivo (Fig 18a). Moreover, CpG induced
production of pro-inflammatory cytokines (i.e. IL-6, IL-12, CCL2, and TNF-α) and antiinflammatory cytokines (i.e. IL-10) relative to mock-treatment, indicating that CpG alone
does not impart a clear M1 or M2 macrophage phenotype (Fig 18b). Further examination
of activation markers revealed that CpG did not modulate CD80 or CD86, but
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upregulated expression of FcγRIII and PD-L1 (Fig 19a). Expression of IL-4 receptor
alpha, an M2 marker, was not altered.
In addition to phenotypical cell surface markers, macrophage metabolism can be
modulated by pro-inflammatory stimuli.54,151 We sought to understand the impact of
CpG-activation on the metabolic state of macrophages by assessing their ECAR
(extracellular acidification rate) and OCR (oxygen consumption rate). We found that
CpG and several other TLR agonists increased ECAR relative to mock-BMDMs,
indicating an increase in glycolytic flux (Fig 18c, Fig 20). However, distinct from other
TLR agonists, CpG elevated the basal OCR of macrophages, signifying higher rates of
oxidative phosphorylation (Fig 18d-e, Fig 20). This metabolic change seen in CpGstimulated macrophages is consistent with metabolic activation seen in dendritic cells in
response to CpG34. Further, we observed that the basal OCR of macrophages increased
with prolonged CpG stimulation (Fig 18f), and corresponded with reduced spare
respiratory capacity (Fig 18g). Collectively, these findings demonstrate that CpGactivation confers a unique metabolic shift in macrophages that occurs without skewing
toward a classical M1 or M2 polarization state.

Lipid metabolism is critical for anti-tumor functions induced by CpG
We next investigated the significance of elevated oxygen consumption in
response to CpG activation by first assessing mitochondrial abundance in macrophages.
CpG-BMDMs exhibited an increase in total mitochondria, in comparison to mockBMDMs (Fig 19b). To further evaluate changes in mitochondrial function, we tested the
contribution of FAO toward elevated oxygen consumption under normal culture
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conditions, in the presence of serum and without other exogenous lipids. FAO was
restricted using etomoxir, an irreversible inhibitor of the enzyme carnitine
palmitoyltransferase 1A (CPT1A) that is involved in fatty acid breakdown. We found that
FAO-inhibition blocked the CpG-induced increase in macrophage OCR without affecting
the maximal respiratory capacity (Fig 21a-b). Furthermore, FAO inhibition with
etomoxir attenuated the capacity of CpG-BMDMs to phagocytose PDAC cells, whether
they expressed inhibitory CD47 or not (Fig 21c-d).
To test the role of FAO for the in vivo anti-tumor activity induced by CpG,
etomoxir was administered daily to mice beginning on day 9 prior to initiating CpG
treatment on day 10. We found that etomoxir treatment blocked the anti-tumor effect of
CpG, whereas treatment with etomoxir alone had no significant impact on tumor
outgrowth (Fig 21e). Importantly, etomoxir treatment also did not alter the abundance of
F4/80+ macrophages in the tumor microenvironment, indicating that the inhibitory effect
observed was not a result of depletion or exclusion of macrophages from the tumor
microenvironment (Fig 21f). Rather, the inhibitory effect of etomoxir was associated
with decreased engulfment of tumor cells by F4/80+ macrophages (Fig 8). Together,
these data demonstrate a key role for FAO in macrophage-dependent anti-tumor activity
induced with CpG.

De novo lipogenesis, but not exogenous fatty acids, are critical for CpG-activated
anti-tumor activity
To define the metabolic changes induced by CpG, we assessed the abundance of
short chain coenzyme A (CoA) species in mock- and CpG-treated macrophages. We
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hypothesized that an increase in FAO in CpG-BMDMs would require breakdown and
incorporation of exogenous fatty acids into acetyl-CoA and TCA substrates. Surprisingly,
we found that the incorporation of labeling from 13C-palmitate into acetyl-CoA and
succinyl-CoA was decreased in CpG-BMDMs, indicating that substrates other than
exogenous palmitate likely serve as precursors for generating acetyl-CoA and succinylCoA in response to CpG stimulation (Fig 22a-b). We next investigated the impact of
CpG on increased fatty acid uptake which is a key feature of M2 macrophages. We found
that CpG-BMDMs did not upregulate fatty acid transporters such as CD36 which instead,
was significantly downregulated in response to CpG stimulation (Fig 19d). In addition,
CpG-BMDMs showed a limited increase in the uptake of BODIPY-labeled palmitate,
indicating that utilization of exogenous fatty acids was not significantly altered in
macrophages by CpG stimulation (Fig 19c). Together, these findings illustrate that while
CpG-macrophages share several metabolic features with M2 macrophages, such as their
oxidative phenotype, they differ significantly in their utilization of exogenous fatty acids.
We proceeded to examine alternative pathways that may support metabolic
activation in CpG-BMDMs. Upon substitution of glucose or glutamine with 13C-glucose
or 13C-glutamine in the media, the relative total pool sizes for acetyl-CoA, succinyl-CoA
and HMG (hydroxymethylglutaryl)-CoA expanded in CpG-BMDMs compared to mockBMDMs (Fig 22c). The percent of acetyl-CoA derived from glucose (M+2 isotopologue)
increased in CpG-BMDMs relative to mock-BMDMs (Fig 6d). This shift was
accompanied by a decreased percent of acetyl-CoA derived from glutamine (M+2
isotopologue) in CpG-BMDMs (Fig 22d). Conversely, incorporation of 13C-glucose into
succinyl-CoA (M+4 isotopologue) decreased upon CpG-stimulation, and was
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accompanied by an increase in labeled, glutamine-derived succinyl-CoA (M+4
isotopologue) in CpG-BMDMs compared to mock-BMDMs (Fig 22e). Together, these
data show that CpG activation of macrophages promotes a shift away from complete
utilization of carbon from glucose and toward glutamine anaplerosis for generating TCA
cycle intermediates such as succinyl-CoA.
The incorporation of glucose into acetyl-CoA and HMG-CoA (a precursor for the
cholesterol synthesis pathway) seen in CpG-stimulated BMDMs was consistent with a
shunting by ATP citrate lyase (ACLY) and de novo biosynthesis of cholesterol/lipids. As
a result, we hypothesized that disruption of ACLY would directly impede the anti-tumor
activity of CpG-activated macrophages. We found that inhibition of ACLY during
macrophage activation attenuated the oxidative phenotype that was induced by CpG and
abrogated the anti-tumor phagocytic activity of CpG-stimulated macrophages even with
combined CD47 ablation (Fig 22f-g). Therefore, our findings demonstrate that CpG can
impart macrophages with a metabolic state that is distinct from that produced by M1 or
M2 polarization. CpG-activated macrophages exhibit a hybrid metabolism, with shared
features of both M1 and M2 macrophages. This unique metabolic state defined by
enhanced oxidative phosphorylation and a shunting of TCA cycle intermediates imparts
macrophages with anti-tumor potential and the capacity to circumvent inhibitory signals
received by CD47 expressed on malignant cells (Fig 23).

Discussion
Macrophages dominate the tumor microenvironment of many cancers, wherein
they are directed toward a pro-tumor role and restricted in their anti-tumor potential. The
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capacity of macrophages to engulf and kill tumor cells is countervailed by their
phenotype as well as inhibitory signals that are present within their surrounding
microenvironment, including the anti-phagocytic molecule CD47, which is overexpressed
by many malignant cells.88,165 Our study identifies a critical role for the central carbon
metabolism of macrophages in defining their anti-tumor functions, including the capacity
to phagocytose tumor cells. We have found that redirection of macrophages toward an
oxidative phenotype is essential for anti-tumor activity induced by CpG stimulation in
vitro and in vivo. Furthermore, CpG-stimulated alterations in macrophage metabolism
were necessary for circumventing inhibitory signals mediated by CD47. Together, our
findings highlight the importance of rewiring macrophage metabolism – by promoting
FAO and redirecting the use of TCA intermediates – as a mechanism to circumvent
negative regulatory signals present on malignant cells and to endow macrophages with
anti-tumor potential.
We found that inhibitory signals expressed by PDAC cells may not always be
dominant in regulating anti-tumor activity by macrophages. Unlike findings in other
cancers, we found that disruption of CD47 activity via antibody-blockade was not
sufficient for inciting anti-tumor responses in an immunocompetent tumor model of
PDAC. Deletion of tumor-expressed CD47 was also not sufficient for inducing in vitro
phagocytosis of tumor cells or in vivo anti-tumor responses. The absence of macrophage
activity in this setting was not due to a lack of pro-phagocytic signals as treatment with
CD47-blocking antibodies, which contain Fc-domains for driving Fc receptor dependent
pro-phagocytic signals in macrophages, also failed to elicit macrophage anti-tumor
activity in vitro and in vivo. Further, in the absence of macrophage activation via CpG
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stimulation, we found that CD47-blocking antibodies were insufficient for stimulating
macrophage phagocytosis of multiple solid tumor types including colorectal,
glioblastoma, melanoma, breast cancer, and lung cancer. Our findings are consistent with
xenograft models of PDAC, where CD47-blockade as monotherapy has shown limited
anti-tumor activity.95 Interestingly, we also did not detect changes in cellular calreticulin
in response to CpG stimulation, which has been shown in other settings to be critical for
stimulating macrophages to engulf tumor cells.73 Rather, our data support a conceptual
model in which inhibitory signals, such as CD47, can be overcome by the activation state
of macrophages, which is defined by core metabolic pathways that govern their antitumor potential. Consistent with this, we observed a significant role for CD47 in
regulating macrophage anti-tumor activity in vitro, but only when macrophages were
activated with CpG, which provides rationale for combining CD47 antagonists with
myeloid agonists. However, this finding was not appreciated in vivo where CpG-induced
anti-tumor activity was indistinguishable between tumors that expressed or lacked CD47.
This may reflect the emergence of additional anti-phagocytic signals that are redundant
with CD47 expressed by tumor cells or even the capacity of CpG to more effectively
activate macrophages in vivo to circumvent inhibitory signals mediated by CD47.
Although M1 and M2 polarization is commonly used to describe macrophage
activity in cancer and may underlie the mechanism of some macrophage-targeted
therapies,166 we found that the anti-tumor properties induced by CpG did not associate
with a classical M1 or M2 phenotype. Even in the absence of M1-polarization, CpG
stimulated macrophages to phagocytose and kill tumor cells, whether they expressed
CD47 or not. These findings support a paradigm of plural activation states, in which
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macrophages may adopt a wide spectrum of phenotypes that are distinguishable by
changes in their functional and metabolic processes. Consistent with this premise,
macrophage biology in microbial infection and obesity has been shown to be determined
by their metabolic phenotype.167 However, the functional consequences of metabolic
changes in macrophages has remained poorly defined in cancer, despite findings to
suggest that lipid metabolism has a pivotal role in governing the anti-tumor functions of
several other immune cell types (e.g. myeloid-derived suppressor cells, dendritic cells,
and T-cells).70–72 Our findings substantiate the importance of lipid metabolism as a
dominant regulator of anti-tumor activity by macrophages and in doing so, demonstrate
that assessing M1 and M2 polarization is not always sufficient for delineating the antitumor potential of macrophages.
We found that the metabolic profile of CpG-activated macrophages exhibited a
unique hybrid of M1 and M2 features, underscoring the need to understand the
contribution of metabolism to macrophage phenotype beyond the M1 and M2 paradigm.
We showed that, similar to M1 macrophages, CpG-activated macrophages redirected
exogenous fatty acids and glucose toward acetyl-CoA generation and de novo lipid
biosynthesis. Our findings are consistent with a known role for CpG in promoting foam
cell
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macrophages.168,169 As seen in M2 macrophages, FAO and glutaminolysis were essential
for the oxidative phenotype of CpG-activated macrophages.63,152 Notably, M2
macrophages are recognized to possess superior abilities than M1 macrophages in
phagocytosing antibody-opsonized tumor cells,170 suggesting an association between
FAO and phagocytic capacity. However, even though inhibition of FAO in CpG52

activated macrophages wholly eliminated their ability to engulf PDAC cells expressing
CD47, inhibition of CPT1A only partially inhibited phagocytosis of CD47 KO cells –
suggesting that FAO was essential for overcoming tumor-expressed CD47, but
dispensable for phagocytosis in the setting of CD47-inhibition. Functionally, FAO in
anti-tumor macrophages may enable the breakdown of large lipid loads after engulfment
of target cells or fulfill the metabolic demands for phagocytosis.171
Competition for limited nutrients can serve as a metabolic checkpoint that
impinges on immune cell activation.172 If exogenous nutrients are limited, alternative
biosynthetic pathways may support cellular metabolism by supplying glucose-derived
fatty acids and reducing equivalents. Using metabolic tracers, we provide evidence of
unique substrate partitioning in CpG-stimulated macrophages that promotes oxidation of
13C-glucose to acetyl-CoA. As acetyl-CoA is diverted into anabolic reactions supporting
lipid biosynthesis, CpG-stimulated macrophages rely on glutamine to support TCA cycle
anaplerosis in a futile cycle similar to that seen in M2-polarized macrophages and Tcells.63,70 Although speculative, increased glutamine flux may support utilization of spare
respiratory capacity in CpG-stimulated macrophages, which could provide a contingency
energy source for buffering against nutrient depletion and oxygen deprivation in hostile
tumor environments.
Changes in the lipid metabolism of CpG-activated macrophages may also alter
plasma membrane properties and in doing so, confer macrophages with an ability to
phagocytose more effectively.157 In turn, changes in membrane fluidity can critically
regulate immunoreceptor signaling during activation of immune cells.173,174 Likewise in
macrophages, CD47-SIRPα signaling and the formation of phagocytic synapses depend
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on membrane rigidity and receptor-clustering.85,174 Macrophage activation by TLRs has
been shown to promote lipid-modifying programs that can alter the abundance of
ceramide and sphingolipid species. These changes in lipid metabolism may influence the
membrane properties of macrophages, as well as their antimicrobial potential.175
Analogously, CpG-activation can shift lipid metabolism in macrophages and
consequently modulate their functions, including cytokine secretion.176 Our data extend
the functional role of TLR-activated changes in macrophage metabolism to include
enhanced clearance of tumor cells, without need for engaging Fc-receptors or blocking
CD47 activity. We speculate that additional mechanisms may operate downstream of
CpG-activation. For example, distinct activation stimuli have been shown to induce
macrophages with “trained memory” in immune functions, characterized by epigenetic
changes with distinct patterns of histone acetylation.177,178 Key acetylation substrates that
may shape the macrophage activation state include acetyl-CoA species derived from
lipids.66,179,180 In CpG-activated macrophages, the dynamic contribution of glucose and
fatty acids to acetyl-CoA pools may similarly support epigenetic changes that facilitate
their anti-tumor role.
CpG is actively being investigated in clinical trials for the treatment of advanced
cancer and our findings provide important insights. We show significant anti-tumor
activity induced with repeated dosing of CpG as monotherapy. In contrast, clinical trials
examining CpG as monotherapy, as well as in combination with immunotherapy and
cytotoxic chemotherapy, have demonstrated limited efficacy in patients with advanced
cancer.45,181,182 However, dosing schedule and route of CpG delivery differ significantly
in these clinical investigations compared to our study. We administered CpG systemically
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and repeatedly every 2 days for five doses with the intent of inciting robust and sustained
macrophage

activation.

oligodeoxynucleotides

In
have

contrast,

most

investigated

clinical

subcutaneous

studies

evaluating

delivery

and

CpG
weekly

administration with the goal of stimulating dendritic cells and mobilizing T cell
immunity. Our data suggest, though, that activation of these cell populations may not
always be required for CpG-induced anti-tumor activity. Since intravenous delivery of
CpG has demonstrated safety in patients,183,184 our findings support a role for sustained
systemic dosing of CpG treatment to stimulate macrophage anti-tumor activity.
Macrophages have emerged as promising therapeutic targets for cancer. Although
they most often adopt pro-tumor functions within tumors, their phenotype is inherently
pliable such that they can be directed with anti-tumor activity. Our data highlight the
implications of activating anti-tumor functions in distinct macrophage populations.
Specifically, we found that CSF1R+ macrophages were necessary for mounting an antitumor response upon CpG-activation, despite this subset of macrophages being
associated with immunosuppression.166 This finding is consistent with reports from other
studies showing the potential to redirect macrophages with anti-tumor properties.32,147,148
However, the mechanisms involved in shifting the role of macrophages from pro- to antitumor have remained poorly defined. Our findings show a role for core metabolic
processes, which act in concert as a key regulator of macrophage anti-tumor activity. This
finding also highlights the importance of the metabolic state of macrophages for
potentiating CD47-based therapies that have, thus far, shown limited efficacy as
monotherapy in PDAC and non-hematopoietic malignancies.95,150 Our study identifies
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macrophage metabolism as a novel therapeutic target that must be appropriately wired to
enable macrophages to carry out anti-tumor functions.
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Figures
Figure 3: Macrophage activation via TLR agonists, but not disruption of CD47,
induces anti-tumor activity in a model of pancreatic cancer.

Figure 3: (a) Conceptual model showing a role for stimulatory (TLR agonists) and
inhibitory (CD47) signals in regulating the anti-tumor activity of macrophages. (b)
Syngeneic mice with established PDAC tumors were treated with 50 µg isotype or antiCD47 Ig on days 10 and 14 after tumor implantation (n=8). Arrows indicate intratumoral
delivery of antibody; error bars represent standard error. (c) Syngeneic mice were
challenged with PDAC tumors in which CD47 was knocked out (CD47 KO) versus
control (CTRL) using CRISPR-Cas9 gene editing (n=5); error bars represent standard
error. (d) In vitro phagocytosis of PDAC cells by BMDMs in the presence of isotype
control or anti-CD47 Ig. (e) In vitro phagocytosis of PDAC cells by BMDMs stimulated
with indicated TLR agonists for 24 hours. (f) Representative immunofluorescence images
showing phagocytosis of PDAC cells (green) by macrophages (BMDM, red) pretreated
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with vehicle (mock) or CpG for 24 hours. Arrows indicate phagocytic events. (g) In vitro
phagocytosis of PDAC cells by BMDMs stimulated with CpG for increasing lengths of
time (n=3), error bars represent standard error. (h) PDAC cell survival following 48-hour
co-culture with macrophages pretreated with vehicle (Mock) or CpG for 96 hours (n=3),
error bars represent standard error. Boxplots represent mean ± SD. Two-tailed Student’s
t-test with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p <
0.001. Results are representative of at least two independent experiments (a-h).
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Figure 4: CD47 expression in murine PDAC tumor cells.

Figure 4: (a) Representative histograms of CD47 expression by live EpCAM+ cells in
tumors and pancreata from age- and gender-matched KPC (KrasLSL.G12D/+; Trp53R172H/+;
Pdx-Cre) and Pdx-Cre control mice. Significance determined by paired t-test of mean
fluorescence intensity (MFI) normalized to isotype stain: ns (not significant); *, p < 0.05;
**, p < 0.01; ***, p < 0.001. (b) Representative histograms of CD47 expression in
distinct KPC-derived tumor cell lines cultured in vitro. (c) Histogram (left) of CD47
expression in control (CTRL) and CD47 knockout (CD47 KO) PDAC.1 cells after
deletion of CD47 by CRISPR-Cas9 (left). Normalized MFI (right) relative to isotype
stain (right). Significance determined by two-tailed Student’s t-test of normalized MFI:
ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001. (d) Representative
immunohistochemistry images showing CD47 expression detected in implanted tumors
derived from PDAC.1 CTRL and CD47 KO cells. Scale bar represents 50 µm. Error bars
represent SD, and results are representative of at least two independent experiments (ad).
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Figure 5: CpG stimulates macrophage-dependent anti-tumor activity in vivo.
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Figure 5: (a) Schematic showing implantation of PDAC tumor cells (day 0) and
subsequent treatment schedule (beginning on day 8) for CpG and methods of macrophage
depletion using clodronate encapsulated liposomes (CEL) and a CSF1R-inhibitor
(CSF1Ri). (b) Two distinct syngeneic KPC-derived PDAC tumors (PDAC.1 and
PDAC.2) were treated with vehicle or CpG beginning on day 10. Waterfall plots show
percent change in tumor volume at day 14 relative to baseline prior to treatment (day 10).
(c) Longitudinal growth curves for PDAC tumors treated with vehicle or CpG (n=6-8);
error bars represent standard error. (d) Shown is frequency of CD11b+ F4/80+
macrophages among total CD45+ cells detected by flow cytometry in PDAC tumors at
day 18, in mice treated with CpG, CSF1Ri, and CEL. Boxplots represent mean ± SD. (e)
Representative images of immunohistochemistry to detect F4/80+ macrophages in PDAC
tumors after treatment with vehicle or CpG with or without CSF1Ri. (f) Longitudinal
growth curves of PDAC.1 tumors treated with CpG and vehicle (no depletion), CSF1Ri,
or clodronate encapsulated liposomes (CEL); error bars represent standard error. Arrows
indicate the initiation of CpG treatment. Two-tailed Student’s t-test with Hochberg
correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001. Results are
representative of at least two independent experiments (a-f).
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Figure 6: Toxicity assessment of etomoxir and CpG in macrophages and PDAC
cells.

Figure 6: (a) Survival of PDAC cells with (CTRL) or without CD47 (CD47 KO)
expression was detected by crystal violet stain, after treatment with vehicle (mock) for 48
hours, defined concentrations of CpG for 48 hours, or 10 mM staurosporine (Stauro) for 6
hours. (b) Survival of BMDMs detected by crystal violet stain, after treatment with
vehicle (mock) for 48 hours, CpG and etomoxir for 48 hours, or 10 mM staurosporine
(Stauro) for 6 hours. Error bars represent standard error, and results are representative of
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at least two independent experiments (a,b). Significance determined by two-tailed
Student’s t-test: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Figure 7: In vivo delivery of CpG to tumor-bearing mice induces systemic cytokine
release.

Figure 7: Syngeneic mice bearing PDAC.1 control (CTRL) or PDAC.1 CD47 KO
tumors were treated with vehicle or CpG beginning on day 10 after tumor implantation.
Peripheral blood cytokines were detected on day 14. Shown are (a) radar plots of fold
change (radial axis) in cytokines detected in the peripheral blood, normalized to vehicletreated mice bearing PDAC.1 control (CTRL) tumors and (b) box plots of cytokine
concentrations detected in the peripheral blood. Two-tailed Student’s t-test with
Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Results are representative of at least two independent experiments (a,b).
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Figure 8: Macrophage engulfment of PDAC.1 cells in vivo.
B

Figure 8: PDAC.1 tumors were harvested at day 14 post-implantation following
treatment with vehicle (Veh), CpG, or CpG + Etomoxir (CpG + Eto) beginning on day
10. (a) Shown is representative images of immunofluorescent co-staining for F4/80+ (red)
and cytokeratin 19 (CK19, green) in tumors treated as indicated. White arrows indicate
macrophages that have engulfed/phagocytosed CK19+ tumor cells. (b) Phagocytic index
was calculated as the intensity of CK19 signal in an F4/80+ macrophage, following
normalization of the CK19 signal across treatment groups. Violin plots show the median,
and every point represents an individual F4/80+ macrophage pooled from tumors in each
treatment group (n = 4-5 tumors per group, four random 20x fields per tumor).
Significance determined by ANOVA comparison of linear mixed effects models: ns (not
significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001
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Figure 9: Depletion of tumor macrophages using anti-CSF1R antibody attenuates
the anti-tumor response of CpG.

Figure 9: Mice bearing PDAC.1 tumors were treated with isotype (Iso) or anti-CSF1R
(aCSF1R) antibody on days 8, 10, 13, 16; vehicle (Veh) or CpG was delivered beginning
on day 10 and every two days thereafter. (a) Representative flow plots are shown of live
F4/80+ CD11b+ CD45+ macrophages from tumors harvested on day 18. (b) Shown is
frequency of F4/80+ CD11b+ macrophages among total CD45+ cells detected by flow
cytometry in PDAC tumors at day 18, in mice treated with Veh + Iso, Veh + aCSF1R,
CpG + Iso, and CpG + aCSF1R. Boxplots represent mean ± SD. (c) Longitudinal growth
curves of PDAC.1 tumors in mice treated with vehicle + isotype (n=4), vehicle + antiCSF1R Ig (n=3), CpG + isotype (n=10), or CpG + anti+CSF1R Ig (n=10). Two-tailed
Student’s t-test with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01;
***, p < 0.001. Error bars indicate standard error.
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Figure 10: Flow cytometric and histologic quantification of tumor-associated
myeloid cells in mice treated with or without a CSF1R inhibitor (CSF1Ri).

Figure 10: (a) Flow cytometric gating strategy for quantifying live (Amcyanneg) CD45+
CD3neg CD19neg F4/80+ CD11b+ macrophages (orange) from singlet cells (gated by FSCA and FSC-H) in tumor digest, compared to bulk unstained tumor cells (blue). Shown are
representative flow cytometric dot plots for samples isolated from digest of PDAC.1
tumors on day 18 following tumor implantation, in mice treated with vehicle, CSF1Ri,
CpG, or CpG + CSF1Ri beginning on day 10. Quantification is shown in Fig 2d. (b)
Shown is quantification of F4/80+ macrophages detected by immunohistochemistry in
PDAC tumors harvested on day 18, following treatment as indicated. Representative
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images are shown in Fig 2e. Two-tailed Student’s t-test with Hochberg correction: ns (not
significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001. Boxplots represent mean ± SD.
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Figure 11: CpG-treatment does not alter T cell activation or infiltration into tumors.

69

Figure 11: (a) Shown are representative flow cytometry dot plots of CD45+ CD3+ T cells
from PDAC.1 tumors collected on day 18 post-implantation. Mice were treated as
indicated with vehicle or CpG on days 10, 12, 14, 16, and 18 after tumor implantation.
Splenocytes from untreated mice were included as a control. (b) Absolute number (per
gram of tumor tissue) of CD4+, CD8+, and regulatory CD4+ Foxp3+ T cells detected in
tumors from vehicle- or CpG-treated mice. (c) Mean fluorescence intensity (MFI) of
Tim3 and PD1 activation markers on CD4+ and CD8+ T cells detected in tumors treated
with vehicle or CpG. Boxplots represent mean ± SD, significance was determined using
two-tailed Student’s t-test: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Figure 12: T cells and natural killer (NK) cells are dispensable for CpG-induced
anti-tumor activity.

Figure 12: (a) Longitudinal growth curves of PDAC.1 CTRL tumors in syngeneic Rag2/- mice (n=8 per group) treated with vehicle (Veh) or CpG beginning on day 10 and
repeated every 2 days for 4 doses. Results are representative of two independent
experiments. (b) Longitudinal growth curves of PDAC.1 CTRL in syngeneic mice (n=5
per group) treated with Veh or CpG beginning on day 10 and repeated every 2 days.,
Mice also received isotype or anti-NK1.1 antibody delivered on days 8, 10, 13, and 16
after tumor implantation. (c) Representative flow cytometry dot plots and (d)
quantification of percent CD45+ NK1.1+ NK cells detected in the peripheral blood on day
14 in mice treated as indicated. Arrows indicate the initiation of CpG treatment. Error
bars represent standard error; boxplots represent mean ± SD. Two-tailed Student’s t-test
with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Figure 13: Dendritic cells are not required for CpG-induced anti-tumor activity.

Figure 13: PDAC.1 CTRL tumors were implanted in syngeneic CD11c-DTR/eGFP mice
and treated as indicated beginning on day 10 after tumor implantation. Diphtheria toxin
(DT) was administered on day 10 and 12 at 12 hours prior to CpG dosing to deplete
CD11c+ cells. (a) Waterfall plot showing percent change in tumor volume at day 13
relative to baseline (day 10), prior to CpG-treatment. (b) Representative flow cytometry
dot plots to detect CD11c+ cells expressing GFP in tumor digests (gated on CD45+
singlets) (c) Shown is frequency of CD11c+ cells identified by GFP expression among
total CD45+ cells detected by flow cytometry in PDAC tumors at day 13. Boxplots
represent mean ± SD. Two-tailed Student’s t-test with Hochberg correction: ns (not
significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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Figure 14: CSF1R+ F4/80+ Ly6C+ macrophages are required for CpG-induced
anti-tumor response.

Figure 14: Mice bearing PDAC.1 tumors were treated with isotype (Iso) or anti-CSF1R
(aCSF1R) antibody on days 8, 10, 13, 16 after tumor implantation; vehicle (Veh) or CpG
was delivered on days 10, 12, 14, 16, 18. (a) Representative flow cytometric gating
strategy for detecting CSF1R-expression on CD45+ F4/80+ CD11b+ macrophages in the
peripheral blood. Shown are representative flow cytometric dot plots from a tumorbearing mouse. (b) Quantification of Ly6Chi monocytes in peripheral blood of tumorbearing mice at day 14 after receiving isotype control (Iso Ig) or anti-CSF1R (aCSF1R)
antibody. (c) Quantification by immunohistochemistry of F4/80+ cells in tumors of mice
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on day 18 after treatment as indicated. (d) Longitudinal growth curves of PDAC.1 tumors
in mice treated with vehicle, CpG, or CpG + anti-Ly6C antibody (Monts). Two-tailed
Student’s t-test with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01;
***, p < 0.001. Error bars indicate standard error. Results are representative of at least
two independent experiments (a,d)
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Figure 15: CpG stimulates macrophage anti-tumor activity in vitro and in vivo that
is independent of the anti-phagocytic signal CD47 expressed on PDAC cells.

Figure 15: (a) Representative histogram plots of SIRPα expression (left) and normalized
SIRPα expression (right) detected by flow cytometry on BMDMs after activation with
CpG for 24-96 hours (n=3). (b) Vehicle (mock) versus CpG stimulated macrophage
phagocytosis of PDAC cells in which CD47 was knocked out (CD47 KO) using
CRISPR-Cas9 gene editing versus control (CTRL) (n=3). (c) Survival of PDAC.1 CTRL
and CD47 KO cells following 48-hour co-culture with vehicle (mock) or CpG activated
macrophages pretreated for 72 hours, using the indicated effector (macrophage) to target
(tumor) ratios (n=3). (d) Coxcomb plots showing distribution and fold change in
leukocyte subsets (as a percentage of CD45+ cells on day 18), for CpG treatment relative
to vehicle treatment in control (left) and CD47 KO (right) PDAC tumors. Radial axis
represents relative fold change in leukocyte subset percentage (n=5-8). (e) Percentage of
CD11b+ F4/80+ macrophages in control and CD47 KO tumors following CpG treatment.
Boxplot represents mean ± SD. (f) Tumor volume of control and CD47 KO tumors
treated with CpG (n=5-8); arrow indicates initiation of CpG; error bars represent standard
error. Two-tailed Student’s t test with Hochberg correction: ns (not significant); *, p <
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0.05; **, p < 0.01; ***, p < 0.001. Results are representative of at least two independent
experiments (a-f).
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Figure 16: CpG-activation induces macrophage engulfment of tumor cells of
multiple cancer types.

Figure 16: (a) Representative histograms showing CD47 expression on the cell surface
of murine tumor cell lines, derived from breast cancer (4T1), melanoma (B16F10), T cell
lymphoma (EL4), glioblastoma (GL261), lung cancer (LLC: Lewis Lung Carcinoma),
and colorectal cancer (MC38) lines. (b) In vitro phagocytosis of syngeneic murine tumor
cells treated with isotype or anti-CD47 antibody, and co-cultured with BMDMs
stimulated with vehicle or CpG (n=3). Error bars represent standard error. Two-tailed
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Student’s t test with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01;
***, p < 0.001.
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Figure 17: Calreticulin abundance in Mock- and CpG-BMDMs.

Figure 17: (a) Representative immunofluorescence stain to detect calreticulin (CRT,
green) expression by CD45+ BMDMs (red) treated with vehicle (mock) or CpG for 96
hours, or thapsigargin (Thaps) for 6 hours. Nuclei are stained with DAPI (blue). (b)
Representative histograms showing calreticulin expression by BMDMs detected by flow
cytometry (left) with quantification (right), showing percentage of BMDMs expressing
CRT after treatment with vehicle (mock), CpG, or thapsigargin. Two-tailed Student’s t
test with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p <
0.001. Boxplots represent mean ± SD. Results are representative of at least two
independent experiments (a,b).
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Figure 18: CpG evokes metabolic changes in macrophages without polarization to
M1 or M2.
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Figure 18: (a) Representative histogram plots of MHCII and CD206 expression (left)
and mean fluorescence intensity (right) for BMDMs pretreated with vehicle (mock) or
CpG for 96 hours, compared with M1 and M2 BMDMs (n=3). (b) Heatmap of cytokine
concentrations produced in vitro by BMDMs treated with vehicle (mock), LPS, or CpG
for 48 hours (n=3), scaled to Log10(Concentration in pg/ml). (c) Extracellular
acidification rate (ECAR) of BMDMs after 24-hour activation with indicated TLR
agonists (n=8), relative to mock-treated baseline. (d) Basal oxygen consumption rate
(OCR) of BMDMs after 24-hour activation with indicated TLR agonists (n=8), relative to
mock-treated baseline. (e) Profile of OCR in BMDMs pretreated for 24 hours with
vehicle (mock) or CpG, in comparison to M1 and M2 BMDMs (n=8). OCR was
measured as picomoles of O2 per minute upon sequential administration with
oligomycin, FCCP, and Rotenone + Antimycin A. (f) Basal OCR of BMDMs following
activation with CpG for increasing durations (n=8), relative to mock-treated baseline. (g)
Spare respiratory capacity of BMDMs treated with vehicle (mock) or CpG for 96 hours
(n=8), shown as the difference between basal OCR and maximal OCR (after addition of
FCCP). Two-tailed Student’s t test with Hochberg correction: ns (not significant); *, p <
0.05; **, p < 0.01; ***, p < 0.001. Results are representative of at least two independent
experiments (a-g).
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Figure 19: Phenotypic differences in mock- and CpG-treated macrophages.

Figure 19: (a) Mean fluorescence intensity (MFI) of activation markers for BMDMs
treated for 96 hours with vehicle (mock) or CpG, in relation to fluorescence minus one
(FMO). Representative histogram plots are shown (n=3). (b) Mitochondrial abundance,
measured as MFI of mitotracker staining, in BMDMs treated for 96 hours with vehicle
(mock) or CpG, in relation to FMO. Representative histogram plots shown for n=3. (c)
Fatty acid uptake of BODIPY-FL16 stain by BMDMs pretreated for 24 hours with
vehicle (mock) or CpG (n=3). (d) Mean fluorescence intensity of CD36 expression in
BMDMs treated with vehicle (mock) or CpG (n=3). Boxplots represent mean ± SD,
significance determined using Two-tailed Student’s t-test: ns (not significant); *, p <
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0.05; **, p < 0.01; ***, p < 0.001. Results are representative of at least two independent
experiments (a-d).
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Figure 20:

Extracellular acidification and oxygen consumption rates in TLR-

activated BMDMs.

Figure 20: (a) Profiles of extracellular acidification rate (ECAR) of BMDMs pretreated
with TLR agonists for 24 hours (n=8), upon sequential administration with oligomycin
(O), FCCP (F), and Rotenone + Antimycin A (R+A); measured as mpH per minute. (b)
Profiles of oxygen consumption rate (OCR) of BMDMs pretreated with TLR agonists for
24 hours (n=8), upon sequential administration with oligomycin (O), FCCP (F), and
Rotenone + Antimycin A (R+A); measured as picomoles of O2 per minute. Error bars
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represent standard error, and results are representative of at least two independent
experiments (a,b).
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Figure 21: Fatty acid oxidation induced by CpG is essential for macrophage antitumor activity.
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Figure 21: (a) Profile of oxygen consumption rate (OCR) in BMDMs treated with
vehicle (mock), CpG, or CpG + etomoxir for 96 hours (n=8). Shown is OCR measured as
picomoles of O2 per minute upon sequential administration with oligomycin, FCCP, and
Rotenone + Antimycin A. (b) Basal OCR of BMDMs treated with vehicle (mock), CpG,
and CpG + etomoxir for 96 hours (n=8). (c) Representative immunofluorescence images
showing phagocytosis of PDAC.1 control (CTRL) or CD47 KO cells (green) after coculture with macrophages (BMDM, red) pretreated with vehicle (mock), CpG, or CpG +
etomoxir for 96 hours. Arrows indicate phagocytic events. (d) In vitro phagocytosis of
PDAC.1 CTRL or CD47 KO cells following co-culture with BMDMs pretreated with
vehicle (mock), CpG, or CpG + etomoxir for 96 hours. (e) Treatment of PDAC.1 CTRL
tumors with vehicle, etomoxir, CpG, or CpG + etomoxir beginning on day 10 after tumor
implantation. Waterfall plot shows percent change in tumor volume at day 14 relative to
baseline prior to CpG-treatment (day 10). (f) Quantification by immunohistochemistry of
F4/80+ macrophages in PDAC tumors on day 14, following treatment with vehicle
(mock), etomoxir, CpG, or CpG + etomoxir. Two-tailed Student’s t test with Hochberg
correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001. Boxplots
represent mean ± SD. Results are representative of at least two independent experiments
(a-f).
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Figure 22: Metabolic rewiring of TCA cycle supports the oxidative phenotype and
anti-tumor activity of CpG-activated macrophages.

Figure 22: BMDMs were pretreated with CpG or vehicle for 96 hours, plated, and then
labeled (i) with the addition of 100 μM 13C-palmitate for 4 hours (n=3) (a,b) or (ii) in the
presence of 25 mM

13

C-glucose or 4 mM

13

C-glutamine for 2 hours (n=3) (c-e). (a)

Percent isotopologue enrichment of acetyl-CoA with addition of

13

Percent isotopologue enrichment of succinyl-CoA with addition of

C-palmitate. (b)

13

C-palmitate. (c)

Relative total pool size of HMG-CoA, succinyl-CoA, and acetyl-CoA after labeling with
tracers (13C-glucose or
CoA from

13

13

C-glutamine). (d) Percent isotopologue enrichment of acetyl-

C-glucose and

succinyl-CoA from

13

13

C-glutamine. (e) Percent isotopologue enrichment of

C-glucose and

13

C-glutamine. (f) Basal oxygen consumption of

BMDMs pretreated as indicated (n=8). (g) In vitro phagocytosis of PDAC.1 CTRL or
CD47 KO cells by BMDMs pretreated as indicated (n=3). Two-tailed Student’s t test
with Hochberg correction: ns (not significant); *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Results are representative of at least two independent experiments (f,g).
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Figure 23: CpG-activation of macrophage metabolism leads to CD47-independent
anti-tumor activity.

Figure 23: A conceptual model showing the oxidative phenotype induced by CpG, and
the multiple metabolic pathways that are essential for supporting CD47-independent
phagocytosis and anti-tumor activity by macrophages.
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Chapter 4: Summary and Future Directions
Summary
In our studies, we identify macrophage metabolism to be a novel and important
determinant of anti-tumor function. Despite the ability of macrophages to engulf and kill
tumor cells, macrophages can be restricted in their ability to execute these functions, even
upon complete loss of anti-phagocytic CD47-receptor on tumor cells. However,
macrophage activation by CpG restored the anti-tumor potential of macrophages in vitro
and in vivo. We found that CpG did not activate a classical M1 or M2 phenotypes
associated with anti- and pro-tumor roles, but stimulated a hybrid of M1 and M2
metabolic features, which proved critical for phagocytosis and anti-tumor activity. Our
findings not only highlight key considerations about CD47-based therapies and
combination strategies for redirecting macrophage activity, but also reveal new directions
for understanding the functional programming of macrophages under physiological and
disease settings – beyond the M1 and M2 paradigm.
Optimizing phagocytic program for engulfing and degrading tumor cells.
Macrophage phagocytosis requires coordination of multiple cellular processes,
which includes engagement of target cells, internalization of cargo into phagosomes,
phagosomal maturation, degradation of cargo, etc.185 Though CpG enables macrophages
to overcome anti-phagocytic CD47 present on the surface of tumor cells, there may lie
downstream processes that remain rate-limiting for phagocytic flux. Understanding how
each of these steps responds to CpG-activation will be essential for maximizing the
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phagocytic function of tumor macrophages and essential for advancing the therapeutic
potential of this approach.
For example, macrophage stimulation through immune sensing pathways induces
cellular features of distinct phagocytic programs. Select TLR pathways (e.g. TLR1/2,
TLR 2/3, and TLR4) induce LC3-associated phagocytosis (LAP), which promotes
immunologically silent clearance of apoptotic cells.57 Likewise, TLR9 stimulation
augments macrophage function by inducing formation of LC3-associated endosomes for
production of type I interferons.59 Examining whether CpG-activated engulfment of
PDAC cells in our experimental model induces LAP apparatuses may provide additional
insight into the mechanisms underlying anti-tumor activity. If CpG-activated engulfment
of PDAC cells does not require LAP, then there may be multiple modes of phagocytosis
that can be harnessed for a cooperative effect. If CpG-activated engulfment of PDAC
cells induces features of LAP, then it will be critical to overcome the immunologically
silent nature of LAP. Doing so will activate a more comprehensive anti-tumor response
involving adaptive immunity and other immune effectors, which we have found to be
muted in the CpG-induced responses observed in our immunocompetent model.
Macrophage clearance of engulfed cells may intrinsically be immunogenically
silent.186 Enhancing the immunogenicity of macrophage-engulfed tumor cells will thus
require stimulation of orthogonal signaling pathways. One such pathway is through
STING (STimulator of INterferon Genes), which responds to cyclic dinucleotides in the
cytoplasm as well as clinical agents in development for cancer immunotherapy.187–189
Degradation of DNA fragments released from engulfed cells, by DNases in the
macrophage cytoplasm, restricts the capacity of macrophages to process tumor cell
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components for antigen presentation.190 STING agonists allow macrophages to overcome
this barrier and may provide additive benefit to the pro-phagocytic effect of CpGactivation by enhancing downstream pathways.
Additional treatment combinations that deserve experimental evaluation include
targeting immunogenic and pro-phagocytic determinants – such as calreticulin-regulators
and MerTK (Mer Tyrosine Kinase).73,191,192 Although we did not observe CpG to induce
macrophage production of calreticulin as a pro-phagocytic signal,55 instigating cellular
stress in the endoplasmic reticulum of tumor cells and macrophages may be sufficient for
calreticulin translocation to the cell membrane.74 Alternatively, engaging established prophagocytic pathways such as MerTK could activate phagocytic programs that
complement the effect of CpG-induced activity.83 Together, examining these pathways
will not only reveal potential anti-tumor targets for therapy, but also provide tools for
integrating potentially distinct phagocytic programs.

Overcoming resistance to CpG-induced anti-tumor activity: Completing the cancer
immunity cycle
Although CpG induces potent anti-tumor activity in our PDAC model, tumors
ultimately relapse, suggesting the development of treatment resistance. One possible
mechanism is the gradual loss of macrophage activity following stimulation. Indeed,
tonic activation of PRR pathways leads to functional tolerance in macrophages.193,194
Loss of effector functions is similarly observed in other immune cells such as T cells
following prolonged inflammation (e.g. viral infection, cancer, etc), leading to metabolic
impairment and functional exhaustion.195,196 Whether macrophages undergo similar loss
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of anti-tumor functions is unknown; thus, their metabolic and functional states should be
assessed during periods of tumor relapse. If macrophages expression of PD1(programmed death-1) activation markers indeed signify functional exhaustion,197 it
may be possible to rescue their activity, as demonstrated with immune checkpoint
modulation in T cells. Other experimental strategies for overcoming the hurdle of tonic
activation include drug holidays during CpG-dosing, clinical agents for enhancing
myelopoeisis (e.g. granulocyte monocyte colony-stimulating factor), or identification of
unique cellular pathways in tolerized cells. Drug holidays or targeting these cellular
pathways in tolerized cells may permit macrophages to ‘reset’ following tonic activation.
Alterations induced by CpG may nonetheless persist, and production and mobilization of
naïve macrophages could be necessary to sustain CpG anti-tumor activity.
An alternative mechanism supporting tumor outgrowth after extended CpG
treatment may be the induction of additional anti-phagocytic pathways during treatment,
including macrophage-expressed PD-1 and tumor-expressed MHC I expressed.94,197 To
address this possibility, it may be necessary to inhibit these pathways together using a
combination strategy – which has proven effective for inciting T cell responses in
pancreatic and other cancers.35,198 A major challenge to this approach will be efficiently
identifying pleiotropic inhibitory pathways and which cell populations that they are
expressed on; if inhibitory receptors are selectively expressed by specific cell populations
in the tumor microenvironment, then depletion of these cell populations may represent a
strategy for ablating anti-phagocytic pathways.
A third strategy for preventing tumor relapse would be to stimulate a consummate
immune response involving other immune effectors, such as cytotoxic T cells. Indeed,
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CD47-blockade effectively enhances antigen presentation by dendritic cells and
macrophages, in a manner that leads to improved anti-tumor activity by T cells.93,145,199
Similarly, CpG provides an adjuvant effect that bolsters T cell responses with appropriate
co-stimulation (e.g. OX40 agonist).46 Together, these studies indicate that the addition of
other immunostimulatory agents may complete the cancer immunity cycle by also
engaging adaptive immune cells to enact cancer immunosurveillance.

Integrating metabolism of effector cells, tumor microenvironment, and hosts
Immune activation rewires macrophage metabolism, but macrophage-extrinsic
regulators of metabolism include the hostile microenvironment of tumors as well as
cachexia commonly found in patients. These conditions can subvert macrophage function
– and potentially suppress phagocytosis of tumor cells – by depriving macrophages of
critical substrates. For example, hypoxic conditions in tumors sequester macrophages and
supports tumor-promoting functions (i.e. angiogenesis), or drive expression of antiphagocytic CD47 on tumor cells.200–202 Likewise, the metabolic demand for tumor cell
growth drives consumption of essential nutrients, such as glucose and amino acids, that
are also essential for macrophage bioenergetics and function.172 In turn, tumor cells
produce metabolites such as lactate that redirect macrophages toward a pro-tumor
phenotype.203 Under appropriate activation conditions or with metabolic rewiring,
immune cells such as T cells can utilize lactate as a fuel source as well (unpublished
data). Understanding how CpG-activated macrophages harness fuel sources beyond
glucose and fatty acids will reveal opportunities for improving CpG-induced anti-tumor
activity.
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Upon engulfing an apoptotic cell or tumor cell, macrophages effectively double
their lipid content.171 Whether altered lipid metabolism in macrophages serves to meet
bioenergetic demands for executing phagocytosis, or whether these changes are
reactionary to catabolizing a large lipid load remains unclear. For exogenous lipids (e.g.
long chain fatty acids, cholesterol, etc) imported into macrophages and other immune
cells, breakdown products are used to generate epigenetic substrates, such as histone
acetyl groups, and incorporated into components of cellular membranes.157,179,180
Studying the metabolic fate and cellular fate of phagocytosed cargo may reveal essential
conditions underpinning phagocytosis. In particular, assessing CpG-induced changes in
membrane composition and epigenetic landscape of macrophages may provide important
insight into the ontology of their phagocytic programming.

Therapeutic opportunities beyond the primary tumor
Pancreatic cancer is a systemic condition, with approximately 80% of patients
with disseminated disease at the time of diagnosis, with the most common site of
metastasis being the liver.24 The liver is also profoundly affected by repeated systemic
administration of CpG, which induces extramedullary hematopoiesis.159 Whether
extramedullary hematopoiesis instigated by CpG sufficiently generates functional
immune cells for cancer immunosurveillance will

need to be assessed. If so,

lymphocytes arising in the liver may represent an important pool of effectors that can be
readily primed by macrophage antigen presentation, and harnessed for sustained antitumor activity.
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Targeting specific immune populations with CpG administration, however, will
remain a challenge, because systemic treatments often give rise inflammatory responses
that consequently to adverse events. To mitigate this risk, it may be necessary to enhance
the therapeutic index of clinical agents such as CpG when administered systemically.
One approach is conjugation of immune agonists to cell-specific antibodies that target
specific sites while concomitantly modulating other immune pathways.204,205 Another
strategy for macrophage-based therapy is adoptive transfer of engineered or conditioned
macrophages, which is an approach that has shown efficacy in preclinical models for
restoring the function of pulmonary macrophages in hereditary pulmonary alveolar
proteinosis.206,207 Together, these methods represent promising methods for therapeutic
targeting of macrophage metabolism across multiple diseases.
We study a role for cellular metabolism in regulating macrophage function in
pancreatic cancer, but our findings may apply to other diseases as well. Aberrant
functions in macrophages manifest as clinical conditions such as hemophagocytic
lymphohistiocytosis or chronic granulomatous disease – which are respectively
characterized by hyperactivation leading to fulminant inflammation and hypofunction
leading to recurrent infections.159,208,209 Exploiting metabolic pathways or conditions in
these diseases could offer therapeutic benefit for modulating macrophage activity and
restoring normal function. In other diseases, macrophages subsets (e.g. osteoclasts and
microglia) serve as critical mediators of bone homeostasis and clearance of protein
aggregates. Perturbation of physiological functions can contribute to osteoporosis or
neurological disease;210–212 hence, improving our understanding of cellular metabolism
and its role in other macrophage types could elucidate broader therapeutic opportunities.
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Chapter 5: Materials and Methods

Experimental Model and Subject Details
Mice
C57BL/6, Rag2-/- (B6(Cg)-Rag2tm1.1Cgn/J), CD11c-DTR/eGFP (B6.FVB1700016L21RikTg(Itgax-DTR/EGFP)57Lan/J) mice were obtained from Jackson
Laboratories. CD11c-DTR/eGFP heterozygotes were enrolled for tumor studies. Animal
protocols were reviewed and approved by the Institute of Animal Care and Use
Committee (IACUC) of the University of Pennsylvania, and conducted in compliance
with the guidelines for animal research by the National Institutes of Health.

Method Details
Reagents.
TLR agonists were resuspended in PBS (phosphate buffered saline, Thermo
Scientific Fisher) prior to addition to cell culture media at final concentrations of: 1 μg/ml
Pam3CSK4 (Invivogen), 1 μg/ml PolyI:C (Invivogen), 1 μg/ml E. coli LPS (Invivogen),
1 μg/ml flagellin (Invivogen), 1 μg/ml imiquimod (Invivogen), 100 μg/ml ODN1826
CpG DNA (Invivogen and Integrated DNA Technologies). Etomoxir (Sigma) was
reconstituted in DMSO (Sigma) and supplemented into media at a 200 µM concentration;
BMS 303141 (Tocris) was reconstituted in DMSO and added into media at 50 µM
concentration. Thapsigargin (Sigma) and staurosporine (Sigma) were reconstituted in
DMSO and added into media at 10 nM and 1 mM, respectively. For mock-treatment,
PBS or DMSO vehicles were utilized as controls when appropriate.
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Tissue Culture.
Tumor cells were cultured in DMEM (Dulbecco’s Modified Eagle’s Media,
Thermo Scientific Fisher) supplemented with 10% v/v FCS (fetal calf serum, Gemini and
VWR), 2 mM glutamax (Thermo Scientific Fisher), and 10 ng/ml gentamicin (Thermo
Scientific Fisher). Cell cultures and in vitro co-cultures were maintained at 37oC and 5%
CO2. Cell counts were determined using a hemacytometer. For in vitro experiments,
PDAC cells were below passage 15, and for in vivo experiments, cells were below
passage 10.
Generation of BMDMs.
BMDMs were derived by isolating bone marrow from mice euthanized with CO2
overexposure. Following treatment with ACK lysis buffer (Thermo Scientific Fisher).
Bone marrow cells were then cultured in Iscove’s Modified Eagle’s Media (Thermo
Scientific Fisher) supplemented with 10% v/v FCS, 2 mM glutamax, 10 ng/ml
gentamicin, and 10 ng/ml M-CSF (Peprotech) for 7-10 days. Prior to use in experiments,
BMDMs were removed from M-CSF and pretreated with TLR agonists or inhibitors for
indicated durations.
Cell lines.
PDAC.1 (152 PDA) and PDAC.2 (69 PDA) cell lines were derived from PDAC
tumors, as previously described4, which arose spontaneously in KrasLSL.G12D/+;
Trp53R172H/+; Pdx-Cre mice backcrossed onto the C57BLl/6 background (Jackson Labs).
Cell line authentication was performed as previously described4. Isogenic PDAC lines
were established by cloning single cells for in vitro and in vivo experiments. PDAC
knockout lines were generated as previously described (Table 5)213: 1x106 tumor cells
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from isogenic lines were transiently transfected with guide RNAs targeting GFP (5’GTGAACCGCATCGAGCTGAA-3’) or CD47 (5’-GGAGCCATCCTTCTCATCCC-3’)
sequences. Guide RNAs were inserted into TOPO-plasmids (Qiagen) per manufacturer
instructions, and mixed 1:1 with LentiCRISPR V2 plasmid (Addgene). The plasmid mix
was combined with Lipofectamine 2000 (Thermo Scientific Fisher) and Opti-MEM
(Thermo Scientific Fisher) for transfection mixture. Tumor cells were transfected for 6
hours; at 24 hours post-transfection, cells were treated with 1 μg/ml puromycin
(Invivogen) for 2 days. Following selection, tumor cells were stained for CD47 and
purified as CD47+ and CD47- populations by fluorescence-activated cell sorting.
Reporter cell lines were generated for phagocytosis and anti-tumor assays by transduction
with lentivirus encoding GFP and Click Beetle Green luciferase, joined by a T2A signal
peptide. After expansion, GFP-expressing PDAC cells were isolated using fluorescenceactivated cell sorting.
Flow Cytometry.
PDAC Tumor cell cultures were treated with trypsin (Thermo Scientific Fisher)
and prepared as a single-cell suspension for flow cytometric analysis; BMDMs in culture
were incubated in cell dissociation buffer (Thermo Scientific Fisher) prior to mechanical
detachment and resuspension. For intracellular stains, cells were permeabilized in 0.1%
Triton-X (Sigma) for 15 min. For tumors, samples were harvested upon necropsy,
mechanically separated, and digested in 1 mg/ml collagenase (Sigma) and 100 μUnits/ml
DNase I (Roche). Tumor digests were filtered and resuspended as single cell suspensions.
Cells were treated with Fc-block (BD Pharmingen), then stained with Amcyan live/dead
dye (Thermo Scientific Fisher). For antibody staining (Table 3), cells were washed with
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PBS containing 2% FCS, and stained on ice. Flow analysis was performed using FACS
Canto (BD Biosciences), and singlets were gated on using FSC-H versus FSC-A.
BODIPY-C16 labeling.
BMDMs were seeded at 1x105 cells/well into a 96-well plate and stimulated with
vehicle or 10 µg/ml CpG for 18 hours. Following stimulation, media was replaced with
fresh DMEM supplemented with 10% v/v FCS, 2 mM glutamax, 10 ng/ml gentamicin,
and 1 µg/ml BODIPY-C16 (Thermo Scientific Fisher) for 1 hour. After labeling, cells
were washed, detached, and analyzed by flow cytometry on a FACS Canto.
Phagocytosis assay.
Pretreated BMDMs were mechanically detached and labeled with 5 μM DiI (Life
Technologies), then seeded into a transparent 96-well tissue culture plate at 5x104
cells/well. GFP-labeled PDAC cells were harvested as a single cell suspension and
seeded at 5x104 cells/well. For other tumor cell lines, cell suspensions were labeled with
5 μM DiO (Life Technologies) and washed prior to being seeded at 5x104 cells/well.
Following 4-hour co-culture, samples were washed and fixed in 4% PFA
(paraformaldehyde, Sigma) for 15 min, prior to image collection. For antibody blockade,
PDAC tumor cell suspensions were incubated with 10 µg/ml isotype (2A3, BioXcell) or
rat-anti-mouse anti-CD47 (MiapIAP301, BioXcell) antibodies for 20 min, prior to being
washed and co-incubated with macrophages. Multiple random fields were collected per
replicate, using an Olympus IX83 microscope, and the number of phagocytic events were
scored and averaged for each replicate.
Anti-tumor activity assay.
102

Luciferase-labeled PDAC cells were harvested as a single cell suspension and
seeded into a 96-well tissue culture plates at 5x104 cells/well. Pretreated BMDMs were
harvested by mechanical detachment and seeded at 0:1, 1:1, 2:1, 5:1 macrophage-totumor ratios. After 48-hour co-culture, tumor cell survival was determined using
Luciferase assay system (Promega). Luminescence measurements were performed using
a SpectraMax M3 reader (Molecular Devices). Tumor cell survival was determined by
normalizing luminescence to tumor-only controls.
Immunohistochemistry.
Cryosectioned murine PDAC tumors were fixed in 4% PFA and treated with
0.1% hydrogen peroxide (Sigma). Samples were blocked in 10% goat serum (Vector
Laboratories) in PBS and treated overnight with primary antibodies (Table 4). Secondary
antibody was applied for 1 hour, and samples were stained with ABC HRP kit
(Vectastain) per manufacturer instructions. Samples were then treated with DAB (3, 3 diaminobenzidine) HRP substrate (Vector Labs) prior to counterstaining with
hematoxylin (Sigma) and dehydration. Images were captured using the Olympus BX-43
microscope.
Immunofluorescence microscopy.
Treated BMDMs were harvested by mechanical detachment and seeded into glass
chamber slides (Nunc). Samples were then fixed in 4% PFA, permeablized in 0.1%
Triton-X for 15 min, and blocked with 10% goat serum (Vector Laboratories) in PBS.
Primary antibodies and isotype control were applied overnight and washed; secondary
antibody was applied for 1 hour and washed. Samples were stained with DAPI for 15 min
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and mounted prior to image acquisition. Images were captured using the Olympus IX83
microscope.
Tumor growth studies.
PDAC cells were harvested from culture, washed, and prepared as a single cell
suspension for implantation into the subcutis of C57Bl/6 mice. Rat-anti-mouse anti-CD47
(MIAP301, BioXcell) and isotype control antibodies (2A3, BioXcell) were diluted in
saline, and 50 µg of each antibody was delivered intratumorally on days 10 and 14 after
tumor implantation, as previously described (Table 5).93 Tumor-bearing mice were
treated with vehicle (PBS) or 50 μg CpG by intraperitoneal injection every other day,
beginning on day 10. For macrophage depletion: 200 μl of clodronate-encapsulated
liposomes (clodronateliposomes.org) was delivered by retroorbital injection into mice,
400 μg of anti-CSF1R Ig (AFS98 , BioXcell) diluted in saline was delivered by
intraperitoneal injection, or GW2580 (AdooQ) was delivered daily at 160 mg/kg by oral
gavage. For natural killer cell depletion, 200 μg anti-NK1.1 Ig (PK136, BioXcell) diluted
in saline was delivered by intraperitoneal injection; diptheria toxin (Sigma) was
administered by intraperitoneal injection at 8 ng/gram body weight. Etomoxir (Sigma)
was resuspended in PBS and delivered daily at 40 mg/kg by intraperitoneal injection as
previously described (Table 5)214. Tumor volume was monitored by caliper measurement
and calculated using a formula for an ellipsoid: Volume = 1/2 x (Length) x (Width)2.
ECAR and OCR measurements.
BMDMs were pretreated with TLR agonists or inhibitors and seeded into XF96well plates (Agilent) at 1x105 cells/well. Prior to measurements, samples were washed
and incubated in Seahorse media (Agilent) supplemented with 0.5 mM D-glucose
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(Sigma). The mitostress kit (Agilent) was prepared per manufacturer instructions by
loading 1.5 µM oligomycin 1.5 µM FCCP, and 1 µM rotenone/antimycin A into injection
ports. Measurements were made using an XF96 Extracellular Flux Analyzer (Agilent)
and results processed with Wave v2.2.0 software.
Cytotoxicity studies.
BMDMs and tumor cells were seeded at 1x105 cells/well into a 96-well plate and
treated with inhibitors diluted in Dulbecco’s Modified Eagle’s Media supplemented with
10% v/v fetal calf serum, 2 mM glutamax, and 10 ng/ml gentamicin. After 4 hours, the
media was removed, and samples were stained with 0.05% w/v crystal violet (Sigma) in
20% ethanol/80% H2O. Samples were then washed and optical density measured at 570
nm using a Spectramax M3 spectrophotometer. Cell viability was determined by
normalizing optical density of treated conditions to mock-treated controls.
13C metabolite tracing.
After pretreatment with CpG or vehicle for 96 hours, macrophages were counted
and seeded at 4x106 cells per sample. For glucose and glutamine labeling, U-13Cglucose and U-13C-glutamine (Cambridge Isotope Laboratories) were substituted into
DMEM supplemented with 10% v/v dialyzed FCS (Life Technologies), 4 mM Lglutamine (Sigma), and 25 mM glucose (Sigma). Cells were incubated at 37 °C in labeled
media for 2 hours prior to harvest. For palmitate labeling, cells were cultured in DMEM
supplemented with 100 µM U-13C-palmitate (Cambridge Isotope Laboratories),10% v/v
charcoal-stripped FCS (Life Technologies), 4 mM L-glutamine (Sigma), and 25mM
glucose (Sigma) for 4 hours. Both tracer experiments included unlabeled control samples
not exposed to 13C-labeled substrates. After incubation, cells harvested and placed on
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ice. Samples were then pelleted, washed in cold PBS, and harvested in 750 μl of ice-cold
10% trichloroacetic acid (Sigma-Aldrich, St. Louis, MO cat. #T6399) and internal
standard containing 13C315N1-labeled acyl-CoAs generated in pan6-deficient yeast
culture were added to each sample in equal amounts.215 Acyl-CoA thioester were
analyzed by LC-MS/HRMS using an Ultimate 3000 autosampler coupled to a Thermo Q
Exactive Plus instrument in positive ESI mode using the settings described previously. 216
Isotopologue enrichment in cells exposed to 13C labeled substrates was calculated using
unlabeled control samples not exposed to 13C substrate as previously described.217 For
relative total pool quantitation, the total AUC for each acyl-CoA species (sum of all
relevant isotopologues) was normalized to the AUC for the 13C315N1-labeled internal
standard specific for that species. As previously described (Table 5),215,218 samples were
centrifuged at 1,200xg for 10 min at 4 °C and pulse-sonicated with a probe sonicator
(Fisher Scientific). Lysates were centrifuged at 15,000xg for 15 min, and the supernatants
were further purified by solid-phase extraction using (OASIS HLB) columns.
Supernatants were then applied, and columns were washed with 1 ml H2O. Analytes
were eluted in 25 mM ammonium acetate in methanol and evaporated to dryness
overnight by N2 gas. Samples were resuspended in 50 μl of 5% 5-sulfosalicylic acid and
10 μl injections were applied in LC/ESI/MS/MS analysis. Isotopologues were designated
as unlabeled (M+0), containing one 13C isotope (M+1), two 13C isotopes (M+2), etc
following tracer labeling.
In vivo phagocytosis.
Frozen sections of PDAC tumors were fixed for 20 min in 4% PFA, followed by
permeablization in ice-cold methanol for 20 min. Samples were blocked for 1 hr in 10%
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goat serum and stained for 4 hr in primary antibodies (rabbit-anti-mouse cytokeratin, ratanti-mouse F4/80). After washing, secondary antibody (488 goat-anti-rabbit, 568 goatanti-rat) was applied for 1 hr. Samples were washed, and images were captured using an
Olympus IX83 microscope. Background reduction was performed in CellSens software
(Olympus) and images were subsequently processed using EBImage software analysis in
R to perform color deconvolution, adaptive thresholding of F4/80 signal, gaussian blur,
and binarization of signal. Size exclusion was applied to remove particles with a radius
less than 10 pixels or greater than 200 pixels. The green (CK) signal was normalized
intrinsically for each image to minimize variability in staining intensity. The phagocytic
index was determined by calculating the normalized green (CK) intensity within each
F4/80+ cells, and the normalized phagocytic index was calculated by taking the ratio of
normalized green (CK) intensity to cell size.
Cytokine analysis.
Peripheral blood was collected by tail vein bleed on day 14, and the serum
fraction was isolated following centrifugation at 10,000xg for 15 min. For in vitro
experiments, 1x106 macrophages were cultured in 1 ml of media. Supernatant was
collected following 48 hour activation with cytokines and TLR agonists. Serum and
supernatants were analyzed per manufacturer instructions using cytokine bead array kits
(BD Biosciences) for IL-1β, IL-4, IL-6, IL-1β, IL-12, IFN-γ, TNF-α, and CCL2. Beads
were analyzed using a FACS Canto II.
Statistics and software analysis.
P-values were calculated using a two-tailed unpaired Student’s t-test and
Hochberg correction for multiple comparison testing, unless stated otherwise. Linear
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mixed effects models (LMEM) were built to include random effects for each cell and
image fields; statistical differences between treatment conditions were determined by
ANOVA comparison of LMEM models. P-values of 0.05 or less were considered
significant. Error bars indicate standard deviation unless stated otherwise. Data analysis
and graphical design was performed using R software (v3.4.3), R-studio, and additional
R-packages: ggplot2, dplyr, reshape2, EBimages, lme4, and heatmap.2 (Fig 5). Flow
cytometric analysis was completed using FlowJo (v10.3), and figure design utilized
Adobe Illustrator CS6.
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Tables: Reagents
Table 3: Flow cytometry and immunohistochemistry antibodies.

Flow cytometry and immunohistochemistry antibodies
Antibody
Manufacturer
Clone
FITC anti-mouse F4/80
FITC anti-mouse CD8b
PE anti-mouse I-A/I-E
PE anti-mouse SIRPα
PE anti-mouse CD16/32
PE anti-mouse CD36
PE anti-mouse CD40
PE anti-mouse CD64
PE anti-mouse CD80
PE anti-mouse CD86
PE anti-mouse PD-L1
PE anti-mouse CD366 (TIM3)
PerCP-Cy5.5 anti-mouse CD11b
PerCP-Cy5.5 anti-mouse CD3a
APC anti-mouse CD19
APC anti-mouse CD206
APC anti-mouse NK1.1
APC anti-mouse CD115 (CSF1R)
APC anti-mouse FoxP3
APC anti-mouse F4/80
APC anti-mouse CD47
APC-Cy7 anti-mouse CD45
APC-Cy7 anti-mouse Ly6C
PE-Cy7 anti-mouse CD45
PE-Cy7 anti-mouse PD1
PacBlue anti-mouse CD3
PacBlue anti-mouse CD4
PE rat IgG2a Isotype
APC rat IgG2a Isotype

eBioscience
Biolegend
BD Pharmingen
eBioscience
eBioscience
Biolegend
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
BD Pharmingen
Biolegend
BD Pharmingen
BD Biosciences
Biolegend
Biolegend
R&D Systems
eBioscience
Biolegend
eBiosciences
Biolegend
BD Pharmingen
BD Pharmingen
BD Biosciences
Biolegend
Biolegend
eBiosciences
BD Biosciences
BD Biosciences
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BM8
YTS156.7.7
M5/114.15.2
P84
93
101306
3/23
X54-5/7.1.1
16-10A1
GL1
MIH5
RMT3-23
M1/70
145-2C11
6D5
C068C2
FAB7614R
AFS98
FJK-16s
BM8
Miap301
30-F11
AL-21
30-F11
RMP1-30
17A2
RM4.5
N/A
N/A

Table 4: Immunohistochemistry and immunofluorescence antibodies.

Immunohistochemistry/Immunofluorescence antibodies
Antibody
Manufacturer
Clone
Rat anti-F4/80 Ig
Rat anti-CD47 Ig
Rabbit anti-Cytokeratin
Rabbit anti-Calreticulin Ig
Rat anti-CD45 Ig
Rabbit isotype Ig
Biotin goat-anti-rat Ig
488 goat-anti-rabbit Ig
568 goat-anti-rabbit Ig

eBioscience
eBioscience
Abcam
Abcam
BD Pharmingen
Santa Cruz Biotechnology
BD Pharmingen
Life Technologies
Life Technologies
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BM8
Miap301
EPNCIR127B
EPR3924
30-F11
Sc-3888
N/A
N/A
N/A

Table 5: Methods and software references.

Methods References
Method
Delivery of CD47-antibody
CRISPR/Cas9 expression
Etomoxir dosing
13
C metabolite tracing
Lme4 package

EbImage package

ggplot2 package
dplyr package
reshape2 package
heatmap.2 package

Pubmed Central ID & References
PMC4598283
PMC3712628
PMC4892846
PMC3802537
Douglas Bates, Martin Maechler, Ben Bolker, Steve Walker (2015).
Fitting Linear Mixed-Effects Models Using lme4. Journal of
Statistical Software, 67(1), 1-48.
Gregoire Pau, Florian Fuchs, Oleg Sklyar, Michael Boutros, and
Wolfgang Huber (2010): EBImage - an R package for image
processing with applications to
cellular phenotypes. Bioinformatics, 26(7), pp. 979-981,
10.1093/bioinformatics/btq046
H. Wickham. ggplot2: Elegant Graphics for Data Analysis.
Springer-Verlag New York, 2009.
Hadley Wickham (2011). The Split-Apply-Combine Strategy for
Data Analysis. Journal of Statistical Software, 40(1), 1-29.
Hadley Wickham (2007). Reshaping Data with the reshape Package.
Journal of Statistical Software, 21(12), 1-20.
Gregory R. Warnes et al. Schwartz and Bill Venables (2016). gplots:
Various R Programming Tools for Plotting Data. R package version
3.0.1.
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